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Abstract:
New treatment strategies are desperately needed for treating skeletal malignancy.
Skeletal malignancies can be either primary cancer that originated in the bone, such as
osteosarcoma, or metastatic cancer that spread from another organ to the skeleton, as
in the case of breast or prostate cancer. In this thesis, I will detail two projects that
focus on the discovery of new treatment strategies for both primary skeletal malignancy
and metastatic skeletal malignancy.
The first project focuses on the primary skeletal malignancy, osteosarcoma, a
rare cancer that is commonly diagnosed in children and young adults and metastasizes
to the lungs.

The survival rate for lung metastatic patients is dismal and has not

improved in the decades since the approval of combination chemotherapeutics for
treatment. Our recent work shows that targeting the epigenetic changes is effective in
treating osteosarcoma as well as the resulting lung metastases.

Using preclinical

mouse models, using FDA approved pan-histone deacetylase (HDAC) inhibitors
panobinostat and romidepsin we can significantly reduce the growth of primary
osteosarcoma the resultant lung metastases as well as prevent the formation of these
metastases. We propose that HDAC inhibition of HDACs could be effective in treating
patients with primary and lung metastatic osteosarcoma.
The second project focuses on metastatic prostate cancer. By investigating the
interactions of bone resident mesenchymal stem cells (MSCs) and prostate cancer
cells, we discovered that secreted factors from the MSCs, including interleukin 28 (IL-

viii

28), promote the evolution of apoptotic resistant prostate cancer cells.

The signal

transducer and activator of transcription proteins (STAT) signaling pathway in these
MSC educated prostate cancer cells becomes altered making them sensitive to STAT3
inhibition. Treatment both in vitro and in vivo with the small molecule STAT3 inhibitor,
S3I-201 effectively kills the apoptotic resistant prostate cancer cells. We propose that
prostate cancer cells are selected by MSCs in the bone microenvironment to become
resistant to chemotherapies (e.g., docetaxel) while at the same time become more
sensitive to STAT3 inhibition. Based on these findings, we believe that targeting STAT3
signaling is a therapeutic option for men with incurable bone metastatic prostate cancer.

ix

Chapter 1: Cancer and Metastasis of the Skeleton

Cancer Overview:
Cancer affects nearly everyone at some point, be it by personal diagnosis or by the
diagnosis of a friend or family member. In 2020, 1.8 million new cancer diagnoses and
over 600,000 deaths are estimated in the United States [1].

Cancer occurs when

abnormal cell proliferation creates a mass of cells called a tumor. Tumors can be
benign or malignant. Benign tumors are non-cancerous, meaning that they do not have
the ability to invade local tissue and spread to other parts of the body. However, they
can still be dangerous depending on their size and the area of the body that they form.
Malignant tumors are always dangerous and can lead to fatalities due to their ability to
metastasize, or spread, to other tissues and organs.
The multifaceted complexity of cancer cells was summarized in 2000 by Robert
Weinberg and Douglass Hanahan as the “hallmarks of cancer.” Six hallmarks were
initially proposed, with 2 additional hallmarks, and 2 enabling characteristics that lead to
development of “hallmarks” being added in 2011 as our understanding of the disease
continues to develop [2, 3].

These hallmarks help to describe what changes are

necessary for a normal cell to become a cancer cell. These changes are simplistically
described in (Table 1). One hallmark, deregulated metabolism, which was observed by
Otto Warburg and called the “Warburg effect,” led to a Nobel prize. Normal cells use
oxidative phosphorylation for energy production, but cancer cells switch to using a less
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efficient form of metabolism know as glycolysis. Otto Warburg hypothesized that this
metabolomic change was actually a cause of cancer [4, 5]. Despite extensive
knowledge about carcinogenesis, we still have much to learn about the biology of
cancer cells and how they interact with other cell types to develop the most insidious
aspects of the disease such as metastasis. Approximately 90% of cancer deaths are
due to metastatic progression [6], therefore it is of utmost importance to focus on
understanding and developing new treatment options for patients with metastatic
disease [7].

Table 1: The hallmarks of cancer and how each hallmark changes a normal cell to
become a cancer cell.
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Metastasis Overview:
The process of a primary tumor relocating and establishing in a distant site is known as
metastasis. The metastatic cascade is a multistep process that begins with the primary
tumor invading the local stroma and intravasating either the blood circulatory system
and/or the lymphatic system (Figure 1) Most solid tumors are epithelial in origin and do
not readily invade and migrate. It has been proposed that epithelial tumor cells undergo
an epithelial to mesenchymal transition (EMT) to acquire traits that promote migration
and invasion into the underlying basement membrane where they can gain access to
vasculature.

A key protein involved in the process is E-cadherin.

E-cadherin is

recognized as a tumor suppressor gene that functions in maintaining cell-to-cell
contact/adhesion of epithelial cells. It has been demonstrated both in vitro and in vivo
using murine models that expression of E-cadherin can suppress invasion and
metastasis [8, 9]. In metastatic cancer cells, however, expression of E-cadherin is lost,
whereas expression of N-cadherin is increased [10]. This in turn can promote invasion
and metastasis. In breast cancer cells, expression of N-cadherin promotes adhesion to
endothelial cells and interaction with fibroblast growth factor receptor (FGFR). During
stimulation with fibroblast growth factor (FGF), these cells upregulate matrix
metalloproteases (MMPs), specifically MMP-9, causing the breast cancer cells to
become more invasive and metastatic [11] [12].

In prostate cancer, N-cadherin

expression is correlated with castration resistance, and an in vivo study treatment with
an antibody to block the extracellular domain of N-cadherin significantly inhibited
prostate cancer proliferation and metastasis [13].

Once the cancer cells have

successfully invaded the local stroma, they can intravasate into either the blood stream
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or lymphatic system [14]. The loss of contact with other cells and extracellular matrix
normally triggers a type of cell death called anoikis. To avoid anoikis, cancer cells
commonly upregulate genes for anti-apoptotic proteins such as cellular FLICE-like
inhibitory protein (c-FLIP) and B-cell lymphoma 2 (BCL-2) family proteins [15].

To

survive the circulating tumor cells must evade immune detection and/or create an
immunosuppressive environment while traveling through the body [16]. Cancer cells
must then extravasate at distant sites. At this point they can remain dormant sometimes
for decades, before they eventually begin to proliferate and create a secondary tumor
[17].

Figure 1: An illustration of the five major steps in the metastatic cascade.
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Interestingly, certain primary tumor types have a predilection to colonize specific
secondary organs, as is the case of prostate cancer metastasizing to the skeleton. In
1889 Stephen Paget proposed the “seed and soil” theory, after studying autopsy
records of breast cancer patients. His theory states that a metastatic site is determined
by interactions between “seeds”, (the cancer cells), and “soil”, (the microenvironment of
metastatic site). He proposed that the seeds will only establish in fertile soil, meaning
that the metastatic site is not random [18]. This theory was challenged by James Ewing
in 1928 who proposed that metastasis is determined by random dispersion through the
circulatory or lymphatic system and therefore is determined by anatomy [19]. Nearly 50
years later, the validity of both theories was confirmed by a series of experiments by
Josh Fidler, who demonstrated that melanoma cells preferentially colonized the lung.
When radio-labeled melanoma were injected intravenously into mice, they distributed to
all organs, supporting the Ewing hypothesis, but they would only survive and grow in the
lung, supporting the Paget hypothesis [20]. When lung and renal tissues were implanted
into the muscle tissue of mice injected with melanoma cells, metastatic outgrowth only
occurred in the implanted lung tissue and the lungs of the mice [21].

Therefore,

different metastatic sites have “fertile soil” for different “seeds,” or cancer types. To
better understand why certain cancers, develop and/or metastasize to bone, it is
essential to understand the biology and environment of the skeleton.

The Human Skeleton:
The skeleton is most commonly thought of as the structural support for the body and a
source of protection for our internal organs. However, the skeleton is actually a much
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more complex, multi-functional organ. For example, it acts as the storage facility of
calcium and houses the bone marrow, where important stem cell populations of
hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) reside [22].
Hematopoietic stem cells differentiate into the different blood cells and MSCs
differentiate into, adipose, cartilage, muscle- and bone-forming cells [23, 24].
Type 1 collagen constitutes approximately 95% of the bone [25]. Whereas noncollagenous proteins and proteoglycans make up the rest of the bone matrix. A calcium
containing compound hydroxyapatite, (CA10[PO4])6[OH]2), is responsible for mineralizing
and hardening the matrix of the bone, which is composed of non-mineralized type-1
collagen or osteoid. The osteoid is produced by the bone forming cells, osteoblasts [26,
27]. Mineralized bone contains many different growth factors that are held in reserve.
These trapped growth factors such as transforming growth factor beta (TGFb), bone
morphogenic proteins (BMPs), insulin-like growth factors (IGFs), and others can be
released upon bone resorption [28]. The body has five types of bones long, flat, short,
sesamoid and irregular. Long bones include but are not limited to the tibia, femur,
fibula, humorous, radius and ulna. Short bones are bones that mediate little to no
movement and include the small bones in the hands and feet, carpals and tarsals,
respectively. Flat bones function as protection and include the cranium and rib cage.
Sesamoid bones are bones that are surrounded by tendon or muscle, the knee cap is
the largest of these bones. Irregular bones are the rest of the bones that can not be
classified into the other four groups. The vertebra in the spinal column are an example
of irregular bones [29].

Bones consist of two different bone types, cortical and

trabecular or cancellous bone. Cortical bone is the hard-dense exterior of many bones
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including the long bones that account for approximately 80% of the total skeletal mass.
Cortical bone that appear solid are actually porous and allows blood flow and nerve
fibers to innervate the bone [30]. The second type of bone is called trabecular or
cancellous bone, and is found within the bone marrow at the ends of long bones, as well
as in flat and irregular bones. Trabecular bone is less dense and more metabolically
active, contributing to the maintenance of HSCs and MSCs [31].

Skeletal Malignancy:
Malignant bone tumors can be categorized into primary, originating in the bone, or
metastatic, tumors that arise in other organs and subsequently colonize the bone. It
should be noted that there are hematological malignancies such as multiple myeloma
and leukemias that originate in and colonize the bone as well, but they will not be the
focus of this thesis since they were not studied in any of our experiments. Primary bone
cancer comprises a small percentage of cancer diagnoses. In the United States, it is
estimated that approximately 3,500 new cases of bone cancer will be diagnosed in 2020
[32]. Metastatic bone cancer is more common, with prostate being the most prevalent.
Approximately 25% of prostate cancer patients develop bone metastases, and these
patients will have a 5-year survival rate of only 3% [33]. Other cancers have a tendency
to metastasize to the skeleton, including lung, kidney, breast and gastrointestinal. The
percentage of patients who develop bone metastases with these cancers are 12, 8, 6,
and 3% respectively [34].

7

Chapter 2: Primary Skeletal Malignancy and Osteosarcoma

Primary Skeletal Malignancies Overview:
Primary bone cancers include osteosarcoma, chondrosarcoma, fibrosarcoma, giant cell
tumor of the bone and Ewing’s sarcoma. This thesis will focus on treatment primary and
metastatic osteosarcoma; therefore, osteosarcoma and the resultant metastases will be
described in greater detail after the brief overview of other primary bone cancers.

Chondrosarcoma, Fibrosarcoma, Giant Cell Tumor and Ewing’s Sarcoma:
Chondrosarcoma is a cancer of the cells that form cartilage. The most common bones
affected are the pelvis and other long bones such as the femur, humerus and ribs [35].
The lung is most common site for metastasis with 50-70% of high-grade
chondrosarcoma having evidence of lung metastasis [36]. Fibrosarcoma is a cancer of
the fibroblasts, or cells that form fibrous connective tissue. Fibrosarcoma commonly
forms in deep soft tissue or periosteum, the membrane that surrounds the bones. It can
also arise inside bones in the medullary canal, or bone marrow cavity, as either a
primary tumor or metastasis [37]. Giant cell tumor of the bone (GCTOB) also known as
osteocalstoma is an uncommon tumor that is pathologically diagnosed by large
multinucleated osteoclast type cells. GCTOB is rarely malignant, but in approximately
2% of cases, it metastasizes to the lung [38, 39] .

Portions of this chapter have been previously published and are utilized with permission of the publisher. (Appendix A p151)
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Ewing’s sarcoma is a tumor that can grow in the soft tissue surrounding the bones or in
the bone. Primary bone cancers can often be cured with amputation and radiation if
diagnosed before metastasis; if there is evidence of metastasis, the survival rates drop
significantly [40]. This thesis will focus on treatment of primary and metastatic
osteosarcoma so it will be described next in detail.

Osteosarcoma:
Osteosarcoma, the most common primary malignancy of bone, is a tumor of
mesenchymal origin, giving rise to malignant osteoblast-like cells that are characterized
by malignant osteoid deposition [41]. Osteosarcoma accounts for approximately 1000
new cases each year [32].

The lifetime incidence of osteosarcoma has a bimodal

distribution with a peak among adolescents and a smaller peak after the age of 70,
thought to be secondary to long-standing Paget’s disease and radiation [42]. Over 85%
of osteosarcomas are considered primary bone cancers, a de novo bone malignancy of
unknown etiology [43]. A typical patient presentation is an adolescent with a history of
localized pain and swelling near the metaphysis of a long bone with abnormal bone
deposition and periosteal reactivity on x-ray [44]. In the pediatric population,
osteosarcoma accounts for only 5% of malignancies, but due to a high degree of
heterogeneity

and

a

propensity

to

metastasize,

osteosarcoma

contributes

disproportionately to cancer-related death in children and young adults [45].
Prior to the 1970s, osteosarcoma treatment primarily consisted of local surgical
control, normally amputation, with 5-year survival rates of 20% [46] [47].

With the

advent of chemotherapies, including high dose methotrexate, doxorubicin and cisplatin
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(MAP), ifosfamide and etoposide (IE), bleomycin, and vincristine, survival rates
increased to nearly 67% for localized patients. Disappointingly, survival rates have
remained at this level for the past three decades despite advances in our understanding
of the disease [46, 48, 49]. This is due in part to the fact that osteosarcoma is highly
aggressive, exemplified by the fact that approximately 15% of patients will already have
clinically detectable metastases at the time of diagnosis [50, 51]. The lung is the major
site of osteosarcoma metastasis followed by secondary skeletal sites [52]. Current
treatment approaches for patients with lung metastatic disease involves systemic MAP
chemotherapy, both surgical resection of the primary along with metastectomy of all
visible lesions and adjuvant high-dose chemotherapy but 5-year survival for these
patients remains at approximately 20% inversely proportional to the degree of
metastatic disease [52-54]. Clearly, there is room for significant improvement in regard
to how the disease is tackled both at the primary and metastatic site.
Among the challenges faced in developing new agents to combat the disease is
the high degree of osteosarcoma heterogeneity, chromosomal instability, multiple
mechanisms of chemoresistance and, the complex interactions between the cancer
cells and the surrounding bone microenvironment [55, 56]. Recent advances have
clearly defined the path forward, mainly through forging collaborations towards
improving the infrastructure of tumor banking, identifying the top scientific areas of
inquiry [57], creating a scoring system to assign priorities for agents towards translation
based on preclinical data [58], creating international collaborations to identify a standard
chemotherapeutic approach [49], and perhaps most importantly, creating statistical
rules for earlier phase clinical trials [59]. Moving forward, there is now a clear trial
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design and threshold for what would be considered an active regimen for trials in
relapsed patients.

Osteosarcoma Etiology:
Osteosarcoma encompasses a variety of osteogenic and chondrogenic primary bone
tumors. The former is hallmarked by areas of bone formation and can be found within
the bone (central), growing from the inner bone lining (periosteal) or on the outer bone
surface (parosteal). The lesions are easily identifiable by x-ray due to their dense
calcified matrix, but they also contain areas of active osteolysis mediated by mature
bone resorbing osteoclasts. Osteogenic osteosarcoma arises from malignant
mesenchymal stem cells, osteoblast precursors through inactivation of multiple tumor
suppressors although the precise source has been difficult to identify. Studies into
genetic events involved in the genesis and progression of osteosarcoma cancer cells
have revealed a complex landscape that underscores the challenges in defining and
optimizing new therapeutic strategies [55, 56].

Osteosarcoma Cancer Cell Heterogeneity and Chromosomal Instability:
There is a large degree of both inter- and intra-tumor heterogeneity in osteosarcoma,
and these differences impact prognosis and response to therapy. Histologically,
osteosarcoma is diagnosed as a mesenchymal neoplasm producing extracellular matrix
proteins and osteoid [43]. This feature gives rise to the main histologic subtypes of
osteosarcoma: osteoblastic, chondroblastic, and fibroblastic. A study of 570 patients of
the European Osteosarcoma Intergroup demonstrated that, in comparison to the
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traditional osteoblastic subtype, there was better response as indicated by the
percentage of necrotic tumor present upon resection to standard therapy in the
fibroblastic group and a lower proportion of good responders in the chondroblastic
group [60]. In addition to histological inter-tumor differences, there is also significant
intra-tumor heterogeneity with a large number of subclones per biopsy. The degree to
which osteosarcoma exhibits these intratumoral differences has been demonstrated
with immunohistochemistry, flow cytometry and genomic studies [61, 62].
The underlying mechanism for this intratumoral diversity appears to be the
genetic instability observed in osteosarcoma. Osteosarcoma is characterized by a
complex and unstable karyotype with different clones having a unique pattern of
complex chromosomal abnormalities. The tumors exhibit gene amplifications,
aneuploidy and multiple unbalanced chromosomal rearrangements. However, there is
no pathognomonic mutation or translocation such as the Philadelphia chromosome in
CML [63]. The majority of the instability is observed at the chromosomal level and
multiple studies have demonstrated that osteosarcoma has one of the highest rates of
chromosomal mutations, such as structural and copy number variations [63-65]. The
chromosomal rearrangements occur potentially via breakage-fusion-bridge (BFB) where
uneven breaks during anaphase and cytokinesis result in potentially new chromosomes
[63, 66, 67] chromothripsis, a catastrophic event found in 33% of osteosarcomas in
which chromosomes shatter into multiple pieces and are incorrectly, non-homologously
“stitched” back together [68] and; alternative lengthening of telomeres (ALT), a process
that can result in rapid changes to telomere length and produces free ends that could
give rise to end-end interactions that can feed the BFB cycle [69]. ALT has been
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observed in 85% of osteosarcoma and is associated with poorer outcomes [55, 70].
Underpinning

these

chromosomal

rearrangement

mechanisms

is

a

frequent

amplification of DNA helicases. For example, a gain of function in the RECQL DNA
helicase, RECQL4, has been identified in 33% of osteosarcoma patients [71, 72].
RECQL4 is important in DNA replication and repair and aberrant expression has been
shown to highly correlate with a risk for osteosarcoma development. Clearly,
osteosarcoma progression is hallmarked by aberrations in DNA replication/repair
making this area an important angle of therapeutic attack.

Targeting Osteosarcoma DNA Replication and Nuclear Function:
Classic chemotherapies such as doxorubicin and etoposide are geared toward
disrupting DNA replication. Emerging data highlight epigenetic strategies in the
treatment of osteosarcoma. Histone deacetylases (HDACs) are critical for regulating
gene expression and play an important role in cell proliferation. Inhibition of HDACs can
lead to cell cycle arrest, apoptosis and, in some cases, differentiation. Panobinostat, a
broad spectrum HDAC inhibitor, has been approved for use in multiple myeloma, and a
number of pre-clinical studies have shown efficacy for HDAC inhibitors against
osteosarcoma either as a single agent or in combination with other therapies [73-75].
Recently, a combination of panobinostat with the proteasome inhibitor, carfilzomib has
been shown to be highly synergistic in promoting apoptosis of multiple osteosarcoma
cell lines [76].

These data indicate a promising role for HDAC inhibitors for the

treatment of osteosarcoma provide strong preliminary data for the generation of clinical
trials in this area.
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What are Histone Deacetylases (HDACs)?:
HDACs are a group of enzymes that have the ability to remove acetyl groups from
histones and other proteins. The examination of calf thymus extract in 1969 led to the
discovery of these enzymes [77].

Deacetylation of histones changes the nucleosomal

conformation, making the chromatin inaccessible to transcription factors, in turn
silencing genes [78].

This epigenetic gene silencing effect is reversed by a group of

enzymes called histone acetyltransferases (HATs) that acetylate histones, opening the
chromatin and allowing transcription factors access to their promoters [79]. Many nonhistone proteins can become deacetylated by HDACS [80].

Nearly 3 decades later in

1996, the first HDAC was isolated and cloned (HDAC1) [81]. HDACs are numbered
chronologically by the dates that they were discovered. [82] There are 4 classes of
HDACs, including 18 individual HDACs and sirtuins. The sirtuins are named based on
their relation to the yeast protein silent information regulation 2 (sir2) they are unrelated
to the “classical HDACs” but they are included as the third class of HDACs due to the
fact that they are NAD-dependent deacetylase enzymes [83]. NAD-dependent Class I
includes HDAC1, HDAC2, HDAC3, and HDAC8; class II include HDAC4, HDAC5,
HDAC6, HDAC7 and HDAC9; Class III are the sirtuins and include SIRT1, SIRT2,
SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7; class IV solely consists of HDAC11 due to the
fact that it is structurally distinct from the other HDACs [84].
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HDACs Role in Cancer Progression:
HDACs play numerous roles in cancer progression and metastasis by de-acetylating
histones and non-histone proteins. HDACs regulate many cellular processes including
but not limited to cell cycle, autophagy, angiogenesis, apoptosis and DNA damage
response [84]. HDAC inhibition has been shown to cause cell cycle arrest in G1/S or
G2/M phase [85]. Overexpression of HDACs has been implicated in poor prognosis in
liver, lung, breast, pancreatic, prostate, colorectal and gastric cancers. [86-92] On the
other hand, inactivation of certain HDACs has been shown to be oncogenic. For
example, poor prognosis in lung cancer patients is associated with low expression of
class II HDACs, particularly HDAC 10 [87]. In hepatocellular carcinoma (HCC) low
expression of HDAC 6 is a poor prognostic factor for patients that had a liver transplant.
Experimental HDAC 6 knockdown caused an increase in angiogenesis by upregulation
of VEGFA, and also suppressed HCC apoptosis [93].

HDAC Inhibitors for Cancer Treatment:
HDAC inhibitors are a group of chemical compounds that are divided into 5 different
groups based on their chemical structure the include hydroxamates, short-chain fatty
acids, cyclic tetrapeptides, benzamides and most recently hydrazides [94, 95].
Hydroxamates were the first group of HDAC inhibitors synthesized. They include,
belinostat, tricostatin A, tubacin, vorinostat and panobinostat among others. Of the
hydroxamates, vorinostat was the first FDA approved HDAC inhibitor in 2006 for
cutaneous T-cell lymphoma (CTCL). Nearly a decade later, in 2015, another HDAC
inhibitor, panobinostat was FDA approved for the treatment of multiple myeloma [96]
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[97] [98]. Short chain fatty acid HDAC inhibitors include butyrate and valproic acid
(VPA). VPA was FDA approved for epilepsy treatment in 1978 and has been shown to
exhibit anticancer properties as a HDAC inhibitor in many cancers breast, prostate
osteosarcoma, and non-small cell lung cancer [99] [100-103]. Cyclic tetrapeptide HDAC
inhibitors include apicidin, trapoxin A and romidepsin (FK228). Romidepsin was FDA
approved in 2009 for the treatment of CTCL [104]. Benzamide HDAC inhibitors include
SNDX275, MGCK0103 and entinostat (MS-275) of these entinostat was used in clinical
trials but was not effective when compared to vorinostat for multiple reasons including
pharmacokinetic issues and off target toxicities

[105]. The newest group of HDAC

inhibitors, hydrazides, are being developed to selectively inhibit class I HDACs with a
focus on inhibiting specifically HDAC 3 for the treatment of acute myeloid leukemia
(AML) [95].
Although all of the currently FDA-approved HDAC inhibitors are used to treat
hematological malignancies, a growing body of preclinical and clinical data showing that
HDAC inhibition can be effectively used to treat solid malignancies as well.

Two

different phase 1 clinical trials testing HDACi for advanced solid malignancies reported
a complete response using belinostat and a partial response using panobinostat to treat
advanced urothelial carcinoma.

In both studies of the patients had mutations in

ARID1A, suggesting that patients with these mutations could benefit from treatment with
HDACi [106].

In vitro studies in osteosarcoma cell lines have shown that HDAC

inhibitors such as valproic acid can impair oxidative phosphorylation, cytoskeleton
remodeling, cell cycle, angiogenesis and ubiquitin proteasome pathways [107, 108].
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Treatment with vorinostat, which inhibits Class I, II and IV HDACs, can impair the in
vitro invasive potential of murine osteosarcoma cell lines [109].
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Chapter 3: Histone Deacetylase Inhibition Prevents the Growth of Primary and
Metastatic Osteosarcoma
Rationale:
Despite being the most prevalent primary bone cancer, the treatment paradigm for
osteosarcoma, consisting of high-dose methotrexate, doxorubicin, and cisplatin, has
changed little over the past 3 decades [110, 111]. Metastasis is the cause of
osteosarcoma related deaths, with the lungs being the most prevalent site [112].
Tragically, the 5-year event-free survival for patients with lung involvement is only 28%
[113].

Amongst the provocative questions created by the Osteosarcoma Biology

Committee were an improved understanding of metastasis and alterations in copy
number, aneuploidy and epigenetic control of osteosarcoma pathogenesis [114]. Due
to the rarity of the disease, clinical trials are difficult and time consuming to conduct,
underscoring the need for strong preclinical data to inform human trial design. To this
end, we assessed the efficacy of approved single agents and combinations using 5
common human osteosarcoma cell lines, focusing on reported tolerability in clinical
trials, non-overlapping toxicities, pharmacokinetic data, cytochrome P450 metabolism,
and other characteristics that negate drug-drug interactions [115]. Our in vitro data
consistently indicated that the broad spectrum HDAC inhibitor, panobinostat, was
cytotoxic for osteosarcoma cells at very low nanomolar concentrations, a finding
supported by independent studies [115].

Portions of this chapter have been previously published and are utilized with permission of the publisher. (Appendix B p152)
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Panobinostat inhibits all classes of HDACs with varying potency and is currently
approved for use in multiple myeloma patients with ongoing clinical trials for other
malignancies [97]. The primary mechanism of action of panobinostat is disrupting
epigenetic control of transcriptional programs that govern cell growth and survival [116].
However, independent of epigenetic regulation, HDACs can also regulate the activity of
several proteins involved in the cell cycle, the production of reactive oxygen species,
apoptosis, immune surveillance, angiogenesis and tumor metastasis [117].
In vitro studies in osteosarcoma cell lines have shown that HDAC inhibitors such
as valproic acid can impair oxidative phosphorylation, cytoskeleton remodeling, cell
cycle, angiogenesis and ubiquitin proteasome pathways [107, 108]. Treatment with
vorinostat, which inhibits Class I, II and IV HDACs can impair the in vitro invasive
potential of murine osteosarcoma cell lines [109]. Further, osteosarcoma cell lines are
highly sensitive to panobinostat treatment at nanomolar concentrations [115]. Here, we
report, using in vivo models of osteosarcoma, that panobinostat as a single agent is
highly effective at preventing orthotopic osteosarcoma growth, spontaneous lung
metastasis, lung colonization by osteosarcoma cell lines and the outgrowth of
established osteosarcoma lung metastases. Additionally, genetic and pharmacological
studies establish key roles of HDAC1 and HDAC2 in controlling the progression of the
disease.

Results:
Panobinostat prevents the growth of orthotopic osteosarcoma:
We initially assessed the activity of panobinostat in 3 in vivo models of osteosarcoma;
murine K7M2 [118], and human SAOS2 and lung metastatic derived SAOS2-LM7
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osteosarcoma cell lines [119] that can be orthotopically or tail vein inoculated as models
of primary and metastatic disease. qRT-PCR and immunoblot results revealed that
several HDACs were expressed in these osteosarcoma cell lines (Figure 2 a and Figure
5 a). Analysis of the St. Jude PeCan database also revealed the expression of several
HDACs in human osteosarcoma patients (n = 107; Figure 2 b) [120]. In vitro, doseresponse studies on osteosarcoma cell lines established that panobinostat had a similar
IC50 (14.3 nM) in K7M2, SAOS2 (11.98 nM) and SAOS2-LM7 (25 nM) Figure 5 b). As
expected, panobinostat treatment of all 3 cell lines led to increased levels of in
acetylated histone H3 (Figure 5 c).
To initially test the efficacy of panobinostat in vivo we utilized the syngeneic
K7M2 murine osteosarcoma transplant model in immunocompetent Balb/c mice [118].
Mice were intratibially injected with luciferase-expressing K7M2 cells and contralateral
limbs received control injections of saline. Using bioluminescence as a correlate for
tumor growth, mice were randomized into vehicle control (VEH: n=11) or panobinostat
(PANO: n=11) groups. Panobinostat treatment inhibited or significantly delayed primary
osteosarcoma growth (Figure 5 d), where analysis of the average bioluminescence
reveals significant differences between the groups from day 14 onwards (Figure 5 e). Of
note, panobinostat-treated mice were given a drug holiday between days 23-30 due to
diarrhea and anemia that mitigated the observed toxicities but resulted in osteosarcoma
growth. However, upon resuming panobinostat treatment, the disease burden again
plateaued.
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Figure 2: HDAC expression in osteosarcoma cell lines and osteosarcoma patient
specimens.
a. qRT-PCR analysis of HDAC gene expression in human and mouse osteosarcoma cell lines. Gene
expression for each HDAC examined target is normalized to the actin levels for each cell line and
graphed as 2-ΔCT. b. Analysis of HDAC gene expression (RNA-Seq) osteosarcoma (OS) patients (n=107).
Data is shown fragments per kilobase million (FPKM) and generated from the St. Jude PeCan database
(https://pecan.stjude.cloud/proteinpaint/) [120].
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Using a bioluminescence value of 1x106 as the study endpoint, the median progression
time of 21 days for the control cohort was significantly shorter than the 53-day median
for the panobinostat-treated cohort. Treatment was halted on day 56.

At that time

point, only 54% of the panobinostat-treated mice (n = 6/11) had reached an RLU of
1x106 (Figure 5 f).

Upon reaching endpoint, ex vivo X-ray analysis revealed a

significant increase in osteosarcoma induced osteolysis in the vehicle control versus the
panobinostat-treated cohort (Figure 5 g). This was reflected in greater trabecular bone
volumes as measured by high-resolution μCT scan analysis although statistical
significance was not reached (Figure 5 h). Histomorphometry and histological analyses
also revealed no striking differences between the groups (data not shown). However,
consistent with bioluminescence data, we observed that panobinostat significantly
reduced tumor proliferation and enhanced apoptosis indices as measured by phosphohistone H3 (pHH3) and cleaved caspase 3 (CC3), respectively (Figure 5 i, j).

Figure 3-1: Panobinostat treatment impairs primary osteosarcoma growth and
associated bone disease.
a. Analysis of HDAC expression in the K7M2, SAOS2 and SAOS2-LM7 osteosarcoma cell lines. Actin
(representative image) was used as a loading control. Primary mouse mesenchymal stem cells (MSC)
were used as a positive control. Numbers indicate molecular weight (kDa). b. K7M2, SAOS2 and
SAOS2-LM7 cell lines were incubated with the indicated concentrations of panobinostat for 24 hours. Cell
viability (CellTiter blue) is presented as a percentage of vehicle control.
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Figure 4-2: Panobinostat treatment impairs primary osteosarcoma growth and
associated bone disease.
c. Acetylated Histone H3 (AHH3; red) immunofluorescent staining in vehicle control (VEH) and
panobinostat (PANO: 40nM) treated K7M2, SAOS2 and SAOS2-LM7 cells after 16 hr. DAPI (blue) was
used a nuclear stain. d. Spider plot of K7M2 bioluminescence (RLU) over time in individual vehicle
control (VEH; n=11) and panobinostat (PANO; n=11) treated mice. Treatment was initiated 3 days
subsequent to inoculation (blue arrow). Mice were removed from study upon reaching 1x106 relative light
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units (RLU). Representative images show bioluminescence in each group at day 35 with hotter colors
indicating greater tumor burden. e. Average of bioluminescence in vehicle control and treated mice. c.
Kaplan-Meier curve of time to reach clinical endpoint (RLU=1x106) for orthotopic K7M2 cells in the
panobinostat (PANO) and vehicle control (VEH) groups. f. X-ray analysis of tumor induced osteolysis
(arrow) in vehicle control (VEH) and panobinostat (PANO) treated groups. Tumor induced osteolytic area
(TuV) was measured as a function of the total volume (TV) of the marrow cavity. g. μCT analysis of
trabecular bone volume in vehicle control (VEH) and panobinostat (PANO) treated groups. Trabecular
bone volume (BV) was measured as a function of the total volume (TV) of the marrow cavity.

Figure 5-3: Panobinostat treatment impairs primary osteosarcoma growth and
associated bone disease.
h, i. Ex vivo analyses from study endpoint of proliferative and apoptotic indices using phospho-histone H3
(pHH3; red arrows; h) and cleaved caspase 3 (CC3; red, arrows, i) respectively. Scale bars represent
50μm. Asterisks denotes statistical significance (**p<0.01; n.s. denotes non-significance).

Panobinostat treatment impairs spontaneous lung metastasis:
The K7M2 model spontaneously metastasizes to the lung from the orthotopic site at
high frequency [118]. In the vehicle cohort, we observed the median time to detectable
lung metastasis, assessed by the appearance of bioluminescent signal, was 10 days
versus 21 days for the panobinostat-treated mice (Fig 4a). Of note, 27% of the
panobinostat treated cohort (n=3/11) had no evidence of lung metastasis at the study
endpoint (day 56).

Further, lung metastases that did form in panobinostat-treated
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recipient mice were significantly smaller than those formed in the vehicle group (Fig.
4b). In accord with this observation, the number of tumor nodules in hematoxylin and
eosin (H&E) stained sections were significantly reduced in tumor bearing lungs obtained
from panobinostat-treated versus vehicle-treated mice (Fig. 4c). The proliferative
indices, as measured by pHH3, were also significantly lower in the panobinostat-treated
cohort. Conversely, apoptotic indices (CC3) were significantly higher compared to
vehicle control (Fig. 4d, e).

Thus, panobinostat is a potent inhibitor of primary

osteosarcoma growth and metastasis in this aggressive in vivo immunocompetent
model of the disease.
Pretreatment with panobinostat suppresses osteosarcoma lung seeding:
Given

that

panobinostat

treatment

reduced

spontaneous

osteosarcoma

lung

metastasis, we next tested if panobinostat would prevent the distal seeding and
establishment of osteosarcoma in a tail vein pulmonary metastasis model. The purpose
of this in vivo experiment was to determine whether panobinostat would potentially be
effective clinically as a neo-adjuvant or adjuvant therapy post-primary tumor resection in
preventing the seeding of lung with osteosarcoma metastases. Mice were divided into
vehicle (VEH: n=9) or panobinostat (PANO: n=5) cohorts and treated for 5 days prior to
the tail vein inoculation with K7M2 luciferase-expressing cells.
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Figure 6: Panobinostat treatment suppresses spontaneous osteosarcoma lung
metastasis.
a. Kaplan Meier curve of time to progression (TTP) of lung bioluminescence detection in mice bearing
primary (tibial) K7M2 tumors in the vehicle control (VEH; n=11/11) group and panobinostat (PANO;
n=8/11) treated groups. b. Analysis of bioluminescence (AVG. RLU) in spontaneous metastases arising
from orthotopic primary K7M2 tumors in the vehicle control (VEH; n=11/11) group and panobinostat
(PANO; n=8/11) treated groups. c. Tumor volume of lung metastases (arrows) as a percentage of total
volume in H&E stained sections derived from vehicle control (VEH) and panobinostat (PANO) treated
mice. Arrows indicate metastatic lesions. d, e. Ex vivo analyses from study endpoint of proliferative and
apoptotic indices using phospho-histone H3 (pHH3; red arrows; d) and cleaved caspase 3 (CC3; red,
arrows, e) respectively. Scale bars represent 50μm. Asterisks denotes statistical significance (*p<0.05,
**p<0.01; ****p<0.0001; n.s. denotes non-significance).

Bioluminescent analysis revealed an initial drop in both groups after inoculation but
subsequent to engraftment, lower tumor burden and growth rates were observed in the
lungs of the panobinostat-treated mice (Figure 7 a). Analysis of the average
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bioluminescence revealed significant differences between the groups from day 27
onwards (Figure 7 b).

Panobinostat treatment was halted at day 38 post tumor

inoculation as statistical significance had been reached. Disease progression, using the
clinical endpoint of labored breathing or weight loss, was then monitored in the
remaining mice through day 92. At day 74, all control mice had succumbed to lung
metastasis with a median survival time of 54 days (Figure 7 c). In contrast, only 60%
(n=3/5) of the mice treated with panobinostat for 38 days had succumbed at the study
endpoint and the median survival time was significantly higher at 92 days versus the
vehicle cohort.
Detailed analyses of lung metastases revealed far fewer gross surface
metastases in the panobinostat-treated group (Figure 7

d) as well as fewer micro

metastases (Figure 7 e). The metastases were distinct, and regardless of group, did not
display striking differences in morphology or location within the lung tissues.
Interestingly, despite ceasing panobinostat treatment at day 38, proliferative (pHH3) and
apoptotic (CC3) indices remained significantly lower and higher, respectively, in the
panobinostat treated cohort at the study endpoint (Figure 7 f, g). Thus, panobinostattreatment is effective at limiting the colonization of the lung by osteosarcoma cells.
Panobinostat treatment reduces established osteosarcoma lung metastatic
burden:
In pretreatment seeding studies, 40% (n = 2/5) of the panobinostat-treated mice
had detectable tumor burden but remained viable at the study endpoint (day 97) despite
ceasing treatment at day 38.
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Figure 7: Panobinostat prevents seeding of lung metastatic osteosarcoma.
a. Spider plot of K7M2 bioluminescence (RLU) over time in individual pre-treated vehicle control (VEH;
n=9) and panobinostat (PANO; n=5) treated mice. Treatment was initiated five days prior to tail vein
inoculation of the osteosarcoma cells. (blue arrow). Representative images show bioluminescence in
each group at day 35. b. Average of bioluminescence in vehicle control and treated mice. c. KaplanMeier curve of time to reach clinical endpoint in the panobinostat (PANO) and vehicle control (VEH)
groups. Panobinostat treatment was stopped at day 38 (red arrow) once statistical significance in overall
survival had been reached. At day 97, all remaining mice in the panobinostat group were euthanatized
(n=2). d. Lungs from each group were inflated with formalin upon removal and the number of surface
metastases (Metastases #) counted. e. Lung sections derived from each group were stained with
hematoxylin and eosin and the percent tumor volume as a function of total lung volume calculated. f, g.
Ex vivo analyses from study endpoint of proliferative and apoptotic indices using phospho-histone H3
(pHH3; red arrows; f) and cleaved caspase 3 (CC3; red, arrows, g) respectively. Scale bars represent
50μm. Asterisks denotes statistical significance (*p<0.05; **p<0.01; ***p<0.001).
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To assess if the outgrowing established metastases remained sensitive to panobinostat,
a single mouse from this cohort was re-treated with panobinostat at day 90.Within 1
week, the tumor volume, as measured by bioluminescence, was reduced by
approximately 75% (Figure 8). Further, K7M2 metastatic cells isolated from the lungs of
panobinostat-treated mice, which were selected in culture using puromycin (selection
marker for luciferase expressing cells) containing media, remained sensitive to low nM
doses of panobinostat (Figure 8). Thus, these osteosarcoma cell lines did not acquire
resistance to the HDAC inhibitor in vivo.

Figure 8: Panobinostat retreatment reduces outgrowing lung metastatic osteosarcoma.
a-d. Bioluminescent (RLU) analysis of K7M2 lung metastatic growth in mouse #23 treated with
panobinostat until day 38 a. when treatment ceased. At day 90, panobinostat treatment was reinitiated b.
with subsequent imaging at day 97 c. Bioluminescent (RLU) values are shown for each point d.
Treatment cessation and initiation are indicated by red and blue arrows respectively. e. Metastatic K7M2
cells isolated from lung tissue were treated with Panobinostat over 24 hours and the impact on growth
(RLU) determined.

Given that panobinostat impaired osteosarcoma lung seeding, we next tested if this
drug would also reduce the growth of established lung metastases. K7M2 cells were
tail vein inoculated and allowed to establish and grow in the lung. At day 3 postinoculation, mice were randomized based on bioluminescence into vehicle control,
(VEH: n = 12) or panobinostat (PANO: n = 12) cohorts. Within 72 hours of treatment, a
significantly lower growth rate was detected in the panobinostat treated group compared
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to vehicle control and this difference persisted throughout the remainder of the study
(Figure 7 a).

Analysis of average bioluminescence revealed significant differences

between the cohorts from day 13 onwards (Figure 7 b).

Using a clinical endpoint of

1x106 RLU, overall survival was significantly reduced in the vehicle control group (17
days) compared mice treated with panobinostat (44 days) (Figure 7 c). Importantly,
while all vehicle-treated recipients reached the study endpoint by day 33, 75% of the
panobinostat group (n = 9/12) were below this cut-off at day 45. Moreover, analysis of
gross and micrometastases revealed a significantly lower lung metastatic burden in the
panobinostat versus the vehicle cohort (Figure 7 d, e). Finally, analysis of proliferative
(pHH3) and apoptotic (CC3) indices revealed lower and higher rates, respectively, of
osteosarcoma lung metastatic growth in the panobinostat treated mice compared to
vehicle control (Figure 7 f, g).
Patients with synchronous or metachronous lung metastatic osteosarcoma have a
particularly poor prognosis [52]. We therefore, tested the in vivo efficacy of panobinostat
in a model of this disease state, the orthotopic SAOS2-LM7 metastasis model [119].
Again, panobinostat treatment (n = 9) significantly reduced the numbers and growth of
SAOS2-LM7 lung metastases versus the vehicle-treated cohort (n = 8; Figure 10).
Collectively, these models establish panobinostat as an effective single agent treatment
for established lung metastatic osteosarcoma.
HDAC1 and HDAC2 drive osteosarcoma malignancy:
qRT-PCR and immunoblot analysis revealed that several HDACs are expressed
in the osteosarcoma cell lines models used (Figure 2 a and Figure 5 a).
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Figure 9: Panobinostat impairs the growth of established lung metastatic osteosarcoma
a. Spider plot of K7M2 bioluminescence over time in individual vehicle control (VEH; n=12) and
panobinostat (PANO; n=12) treated mice. Treatment was initiated three days post inoculation of the
osteosarcoma cells (blue arrow). Representative images show bioluminescence in each group at day 35.
b. Average of bioluminescence in vehicle control and treated mice. c. Kaplan-Meier curve of time to
reach clinical endpoint in the panobinostat (PANO) and vehicle control (VEH) groups. d. Lungs from each
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group were inflated with formalin upon removal and the number of surface metastases (Metastases #)
counted. e. Lung sections derived from each group were stained with hematoxylin and eosin and the
percent tumor volume as a function of total lung volume calculated. f, g. Ex vivo analyses from study
endpoint of proliferative and apoptotic indices using phospho-histone H3 (pHH3; red arrows; f) and
cleaved caspase 3 (CC3; red, arrows, g) respectively. Scale bars represent 50μm. Asterisks denotes
statistical significance (*p<0.05; **p<0.01; ***p<0.001).

Figure 10: Panobinostat and romidepsin significantly impact the growth of established
lung metastatic SAOS-LM7 osteosarcoma.
a. b. Spider plot (a) of SAOS-LM7 bioluminescence over time in individual vehicle control (VEH; n=8) or
panobinostat (PANO; n=9) treated mice. Treatment was initiated seven days post inoculation of the
osteosarcoma cells. Tumor volumes based on bioluminescence (RLU) were compared at day 147 (b). c.
d. Spider plot (a) of SAOS-LM7 bioluminescence over time in individual vehicle control (VEH; n=8) or
romidepsin (ROMI; n=9) treated mice. Treatment was initiated 7 days post inoculation of the
osteosarcoma cells. Tumor volumes based on bioluminescence (RLU) were compared at day 147 (d). e.
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Representative H&E stained lung sections derived from vehicle control, panobinostat and romidepsin
treated mice. Asterisks denotes statistical significance (*p<0.05; **p<0.01).

Interestingly,

silencing

of

HDAC5

or

HDAC6

significantly

increased

osteosarcoma growth in vitro (Figure 11 a-d), whereas treatment with the HDAC6
selective inhibitor, tubastatin had little impact on osteosarcoma viability with a IC50 of
only 13.88 μM; i.e., approximately 1000-fold less potent than panobinostat (Figure 11
e). Conversely, silencing of HDAC1 or HDAC2 impaired osteosarcoma cell growth
(Figure 12 a, b). Because we noted compensatory expression of HDAC1 upon HDAC2
silencing, we also examined effects of combined HDAC1/2 silencing, which significantly
reduced the growth of the osteosarcoma cells (Figure 12 b). Consistent with these
findings, K7M2 and SAOS2-LM7 cells were highly sensitive to the HDAC1/2 selective
inhibitor, romidepsin with IC50 values of 50 nM and 5 nM that were similar to those noted
for panobinostat (Figure 12 c, d). As romidepsin inhibits other HDAC family members at
higher concentrations [121, 122], we treated HDAC1/2 depleted cells with romidepsin
and found no additional effect on osteosarcoma growth demonstrating the selectivity for
romidepsin against HDAC1/2 at the concentrations used (Figure 12 e).
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Figure 11: HDAC5 and HDAC6 suppress osteosarcoma growth.
a, b. Analysis of HDAC5 levels in K7M2 cells 24 hours subsequent to siRNA silencing (a) compared to
scrambled control siRNA (SCR). Actin was used as a positive loading control. Numbers indicate
molecular weight (kDa). Densitometry graphs illustrate the impact of silencing on HDAC5 levels. The
effect of HDAC5 silencing on cell growth (b) was determined by measuring bioluminescence (RLU). c, d.
Analysis of HDAC6 levels in K7M2 cells 24 hours subsequent to siRNA silencing (c) compared to
scrambled control siRNA (SCR). Actin was used as a loading control. Numbers indicate molecular weight
(kDa). Densitometry graphs illustrate the impact of silencing on HDAC5 levels. The effect of HDAC6
silencing on cell growth (d) was determined by measuring bioluminescence (RLU). e. The effects of the
HDAC6 selective inhibitor tubastatin at varying concentrations on K7M2 viability over 24 hours.
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Figure 12: HDAC1 and HDAC2 contribute to osteosarcoma growth.
a, b. Analysis of HDAC1 and HDAC2 levels in K7M2 cells 48 hours subsequent to siRNA silencing (a)
each HDAC individually or in combination (HDAC1/2) compared to scrambled control siRNA (SCR). Actin
was used as a positive loading control. Numbers indicate molecular weight (kDa). Densitometry graphs
illustrate the impact on HDAC1 and HDAC 2 levels. The impact on cell growth subsequent to silencing
HDAC1 and HDAC2 or HDAC1/2 (b) was determined by measuring bioluminescence (RLU). c, d. The
effect of the HDAC1/2 selective inhibitor romidepsin at varying concentrations over 48 hours on K7M2 (c)
and SAOS2-LM7 (d) cell viability. e. Romidepsin effects on the viability of HDAC1/2 silenced K7M2
compared to scrambled control (SCR) after 24 hours of treatment. Asterisks denotes statistical
significance (*p<0.05; ****p<0.0001; n.s. denotes non-significance).

Given that patients succumb to established lung metastatic osteosarcoma, we
examined the efficacy of romidepsin in treating this stage of the disease. To this end,
mice were tail vein inoculated with luciferase-expressing K7M2 and, after 3 days,
randomized into vehicle (VEH: n=10) or romidepsin treatment cohorts (ROMI: n = 10).
Similarly to panobinostat, romidepsin reduced lung metastatic growth as measured by
bioluminescence (Figure 14 a) and improved overall survival compared to the vehicle
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cohort (Fig. 10b). Again, reduced growth was associated in lower numbers of gross and
micrometastases in romidepsin-treated mice, with an accompanying reduction in
proliferation and increased apoptotic indices (Figure 14 c-f). We also observed that
romidepsin treatment effectively reduced the growth and number of SAOS2-LM7 lung
metastases compared to vehicle (n = 8) (Figure 10 c-e). Based on these data we
conclude that HDAC1 and HDAC2 contribute to osteosarcoma progression and
metastasis.

Figure 13-1: The HDAC1/2 inhibitor romidepsin significantly impacts the growth of
established lung metastatic osteosarcoma and the viability of human osteosarcoma
PDX cell lines.
a. Spider plot of K7M2 bioluminescence over time in individual vehicle control (VEH; n=10) and
romidepsin (ROMI; n=10) treated mice. Treatment was initiated three days post inoculation of the
osteosarcoma cells. (blue arrow). Representative images show bioluminescence in each group at day 35.
b. Kaplan-Meier curve of time to reach clinical endpoint in the romidepsin (ROMI) and vehicle control
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(VEH) groups. c. Lungs from each group were inflated with formalin upon removal and the number of
surface metastases (Metastases #) counted. d. Lung sections derived from each group were stained with
hematoxylin and eosin and the percent tumor volume as a function of total lung volume calculated.

Figure 14-2: The HDAC1/2 inhibitor romidepsin significantly impacts the growth of
established lung metastatic osteosarcoma and the viability of human osteosarcoma
PDX cell lines.
e, f. Ex vivo analyses from study endpoint of proliferative and apoptotic indices using phospho-histone H3
(pHH3; red arrows; e) and cleaved caspase 3 (CC3; red, arrows, f) respectively. Scale bars represent
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50μm. Asterisks denotes statistical significance (*p<0.05; **p<0.01; ***p<0.001). g. Analysis of patient
derived xenograft (PDX; SJOS series) cell line response to panobinostat (PANO; blue dots) and
romidepsin (ROMI: orange dots). (https://braid.stjude.org/masttour/). 1; CY143B, 2; SAOS2, 3; SAOS2LM7, 4;SJOS001105_X1, 5;SJOS001107_X1, 6; SJOS001107_X2, 7; SJOS001107_X3, 8;
SJOS001108_X1, 9; SJOS001112_X1, 10; SJOS010929_X1, 11; SJOS013769_X1 and 12; U20S. AUC
represents area under curve while black dots represent the effectiveness of other reagents.

Osteosarcoma PDX cell lines are sensitive to romidepsin and/or panobinostat:
To determine the robustness of our findings, we examined the sensitivity of patient
derived

xenograft

(PDX)

cell

lines

in

a

publicly

available

dataset

(https://braid.stjude.org/masttour/) [123, 124]. Consistent with our own current and
previous data, analyses reveal a broad sensitivity to romidepsin and/or panobinostat in
PDX (n = 8) cell lines (Figure 14 g) [115, 123, 124]. Interestingly, these studies also
documented the synergistic effects of HDAC and proteasome inhibitors in vitro.
However, in vivo treatment of PDX models with panobinostat and the proteasome
inhibitor, bortezomib, did not prove effective compared to controls [123]. Our previous
in vitro studies and analysis of K7M2, SAOS-LM7 also documented the synergy
between panobinostat and the proteasome inhibitor, carfilzomib (Figure 16)[115]. We
next examined the effect of each reagent alone or in combination (at 1/10 of the dose of
each single agent based on in vitro data) on the orthotopic growth and spontaneous
metastasis of K7M2 in vivo. In contrast to our in vitro data, we observed that, as a
single agent, carfilzomib elicited no effect on primary osteosarcoma growth and
ultimately did not elicit the beneficial effects observed with panobinostat when given in
combination (Figure 16). These data were consistent with previous in vivo studies
examining the efficacy of panobinostat and bortezomib in PDX xenografts [123].
Further, carfilzomib alone had no beneficial effect on spontaneous lung metastasis but
did not subtract from the efficacy of panobinostat when used in combination. These
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data underscore the need for in vivo testing of potentially synergistic therapies identified
in vitro but again support the use of HDAC inhibitors for the treatment of primary and
metastatic osteosarcoma.

Figure 15-1: Carfilzomib has no effect on primary osteosarcoma growth or lung
metastasis in vivo.
a, b. K7M2, and SAOS2-LM7 cell lines were incubated with the indicated concentrations of panobinostat
(PANO), carfilzomib (CARF) or panobinostat plus carfilzomib (CARF+PANO) for 48 hr. Cell viability
(CellTiter blue) is presented as a percentage of vehicle control. c. Spider plot of K7M2 bioluminescence
(RLU) over time in individual vehicle control (VEH; n = 6) carfilzomib (CARF; n = 7), panobinostat (PANO;
n=6) or carfilzomib and panobinostat (CARF+PANO; n = 5) treated mice. Treatment was initiated 3 days
subsequent to inoculation (blue arrow). Mice were removed from study upon reaching 1x106 relative light
units (RLU). Representative images show bioluminescence in each group at day 34 with hotter colors
indicating greater tumor burden.
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Figure 16-2: Carfilzomib has no effect on primary osteosarcoma growth or lung
metastasis in vivo.
d. Average of bioluminescence in vehicle control and treated mice. e. Analysis of bioluminescence
between the groups at day 34. f. Spider plot of K7M2 lung bioluminescence (RLU) over time in individual
mice from each group. Representative images show bioluminescence in each group at day 34. Lung
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bioluminescence was observed by blocking tibia signal with light proof material. g. Analysis of average
bioluminescence in spontaneous metastases arising from orthotopic primary K7M2 tumors. h. Kaplan
Meier curve of time to progression (TTP) of lung bioluminescence detection in mice bearing primary
(tibial) K7M2 tumors in each group. Asterisks denotes statistical significance (*p<0.05).

Discussion:
Although rare, osteosarcoma remains a deadly tumor type, especially for patients with
metastatic disease. Despite therapeutic advances for several solid malignancies, the
treatment paradigm for osteosarcoma has remained frustratingly static for 3 decades.
Specifically, the 5-year event-free survival rate for osteosarcoma with no metastasis is
60%, but this drops to 28% if there is evidence of synchronous metastases [113].
Further, a retrospective analysis of 247 cases of osteosarcoma showed that 13% of
patients present with synchronous lung metastases, while a further 21% will have
metachronous lung involvement within 10 months [52], and these are responsible for
the majority of osteosarcoma related deaths.
Clinical trials of Food and Drug Administration (FDA) therapies for osteosarcoma
treatment are difficult and time consuming to conduct given the relative low incidence of
disease. To identify effective therapies that will motivate clinical trials, we previously
assessed the response of 5 osteosarcoma cell lines 143B, MNNG/HOS, MG63, U2OS,
and SAOS2 to a panel of approved therapeutics [115]. We consistently observed that
the HDAC inhibitor panobinostat compromised the survival of all osteosarcoma cell lines
at low concentrations. These observations are consistent with studies examining the in
vitro effects of panobinostat and other broad spectrum HDAC inhibitors such as
vorinostat on osteosarcoma cell lines [109, 125]. Independent studies conducting an in
vitro screen of drug efficacy on 3 osteosarcoma patient-derived xenografts (PDXs) also
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identified HDAC inhibitors and specifically panobinostat as effective at inducing
osteosarcoma cell death [124]. Importantly, panobinostat was noted to have additive
cytotoxicity in vitro with chemotherapies commonly used to treat osteosarcoma,
doxorubicin and gemcitabine [124]. Collectively, these in vitro studies underscore the
potential for HDAC inhibition for the treatment of osteosarcoma.
To date, no studies have assessed the efficacy of panobinostat as a single agent
on osteosarcoma in vivo. Here, using several complementary models of human and
murine osteosarcoma, we show that panobinostat treatment effectively limits the growth
of primary disease and spontaneous metastasis to the lung, and that it can also prevent
seeding of the lung tissues by osteosarcoma cells. These data (Figure 7) suggest that
applying panobinostat in a neoadjuvant or adjuvant setting for the treatment of primary
disease could greatly reduce the incidence of, or time to, metachronous primary or
metastatic relapse. Importantly, we also showed that panobinostat significantly reduced
the growth of established osteosarcoma lung metastases and greatly extended overall
survival. Panobinostat does have reported toxicities such as anemia and diarrhea at the
doses and frequency used but mice quickly rebounded during the drug “holiday.” Given
the significance of our results it is likely that panobinostat treatment at lower doses or
over longer intervals would remain efficacious. Collectively, these data provide strong
rationale for the design of clinical trials to test panobinostat in canine osteosarcoma and
ultimately humans.

We anticipate that patients diagnosed with lung metastatic

osteosarcoma, who are at most risk and have failed other treatments, represents the
focus cohort for such trials.

42

While presumably the effects of panobinostat are cancer cell intrinsic, there are
also potential benefits on the tumor microenvironment. For example, panobinostat has
been shown to prevent osteoclast formation and function [126]. Additionally, in other
malignancies, HDAC inhibition in combination with HER2 blocking antibodies has been
shown to activate immune cells such as natural killer (NK) cells to improve the
tumoricidal effects on HER2 positive breast tumors [127]. In melanoma, panobinostat
has been shown to not only inhibit the disease but to also augment the expression of
major histocompatibility complex and co-stimulatory molecules in tumor cells, leading to
the activation of antigen specific T-cells [128].

In support of this, the effects of

panobinostat and romidepsin in our study were more striking in the syngeneic K7M2
immunocompetent model compared to the SAOS-LM7 immunocompromised model. We
will be exploring this further as we develop our studies.
In our siRNA studies guided by the expression of HDACs, we found that HDAC1 and
HDAC2 functionally contribute to the maintenance of osteosarcoma.

Interestingly,

silencing of HDAC6 promoted tumor growth but this effect was not observed with the
HDAC6 inhibitor tubistatin, suggesting potentially non-catalytic tumor suppressive roles.
Notably, analysis of public datasets reveals high expression of HDAC1 in PDX models
of osteosarcoma compared to HDAC2 and other HDAC members [129]. Further,
consistent with their roles in osteosarcoma cell fate, HDAC1 and HDAC2 are expressed
in more mesenchymal/osteoblast precursor states, and their inhibition or deletion
promotes osteoblastic differentiation [130].

Finally, although HDAC2 depletion has

been reported to promote the stemness of MG63 osteosarcoma cells, and in vivo data
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indicates a tumor suppressive role for HDAC2 [131], these studies did not assess if
there are compensatory effects on HDAC1 expression.
The key HDAC1 and HDAC2 regulated targets that contribute to the
maintenance of osteosarcoma biology remain to be elucidated but their identification
could lead to the development of more specific targeted therapies for osteosarcoma
treatment.

Regardless, our studies provide a strong rationale for clinical trials that

assess the efficacy of panobinostat or romidepsin for the treatment of metastatic
osteosarcoma. To date, no trials with HDAC inhibitors have been conducted for
osteosarcoma, and we submit these trials should be a high priority, particularly given
the dearth of effective therapies for metastatic metachronous osteosarcoma, and the
fact that both panobinostat and romidepsin are FDA-approved for the treatment of other
malignancies

Materials and Methods:
Cell lines:
K7M2 (RRID: CVCL_V455) (a kind gift from Dr. Chand Khanna, NCI [118]), SAOS2
(RRID:CVCL_0548) and SAOS2-LM7(RRID:CVCL_0515) (a kind gift from Dr. Eugenie
Kleinerman, MD Anderson, [119]), and primary murine mesenchymal stromal cells
(MSCs) were isolated from the cortical bone of C57BL/6 mice. All cell lines were
mycoplasma free (Cat # CUL001B, R&D Systems). All human cell lines were validated
by short tandem repeat (STR Moffitt genomics core) and mouse cell lines via IDEXX
BioAnalytics within the last 6 months.

Cell lines were passaged in recommended

culture medium supplemented with 10% fetal calf serum. All cell lines were transduced
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to express luciferase using Cignal Lenti Positive Control (luc) (Qiagen CAT# 336891).
Positive clones were selected using puromycin.

HDAC qPCR, silencing and immunoblotting:
Total RNA was extracted from cells with TRIzol (Invitrogen) per manufacturer protocols.
HDAC human and mouse primers were synthesized (IDT) (Supplemental Table 1). RTPCR mixtures were generated using SYBR Green reagent (Applied Biosystems, Cat#:
4309155) and reactions were performed and quantified using ABI-7900HT instrument
and SDS 2.3 software per manufacturer protocols (Applied Biosystems).

Total RNA was extracted from cells with TRIzol (Invitrogen) as per manufacturer’s
instructions. HDAC human and mouse primers were synthesized (IDT) (Table 2). RTPCR mixtures were generated using SYBR Green reagent (Applied Biosystems, Cat#:
4309155) and reactions were performed and quantified using ABI-7900HT instrument
and SDS 2.3 software per manufacturer protocols (Applied Biosystems).

Table 2: Human and mouse HDAC primers for qRT-PCR analysis
TARGET
HDAC 1

HUMAN

MOUSE

HDAC 6

5’-GGTCCAAATGCAGGCGATTCCT-3’
3’-TCGGAGAACTCTTCCTCACAGG-5’
5’-CTCATGCACCTGGTGTCCAGAT-3’
3’-GCTATCCGCTTGTCTGATGCTC-5’
5’-GAGTTCTGCTCGCGTTACACAG-3’
3’-CGTTGACATAGCAGAAGCCAGAG-5’
5’-CGCTGAGAATGGCTTTACTGGC-3’
3’-GTGTAGAGGCTGAACTGGTTGG-5’
5’-GCCTCAATCACTGAGACCATCC-3’
3’-GGTGCCTTCTTGGTGACCAACT-5’

5’-TGAAGCCTCACCGAATCCGCAT-3’
3’-TGGTCATCTCCTCAGCATTGGC-5’
5’-GTTTTGTCAGCTCTCCACGGGT-3’
3’-CTTGGCATGATGTAGTCCTCCAG-5’
5’-AACCTCATCGCCTGGCATTGAC-3’
3’-GTAGTCCTCAGAATGGAAGCGG-5’
5’-ACCAGCAGTTCCTGGAGAAGCA-3’
3’-TCCGTCAGCTCCTCTTCTGTCT-5’
5’-TCGCTGTCTCATCCTACCTGCT-3’
3’-GTCAAAGTTGGCACCTTCACGG-5’

HDAC 8

5’-TGTGCTGGAAATCACGCCAAGC-3’

5’-GTCAGCCAAGAAGGTGATGAGG-3’

HDAC 2
HDAC 3
HDAC 5
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Table 2: (Continued)
HDAC
11
Actin

3’-ACCACTCCTCAGCTCTGGAAAC-5’

3’-ACACTTCCCGTCAATCAGGCAC-5’

5’-CTTCTGTGCCTATGCGGACATC-3’
3’-GAAGTCTCGCTCATGCCCATTG-5’

5’-AAGGCATCTCCAGAGCCACCAT-3’
3’-CAGGGTAGATGTGGCGGTTGTA-5’

5’-CACCATTGGCAATGAGCGGTTC-3’
3’-AGGTCTTTGCGGATGTCCACGT-5’

5’-CATTGCTGACAGGATGCAGAAGG-3’
3’-TGCTGGAAGGTGGACAGTGAGG-5’

For analysis of protein levels by immunoblotting, cells were lysed with RIPA (150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 20 mM Tris,
pH 8). Protein concentration was determined by BCA (Pierce, Waltham, MA, USA;
#23225). Blots were blocked in 5% BSA for 1 hour followed by primary antibody.
Primary antibodies for HDAC1, HDAC2, HDAC3, and HDAC5 were purchased from Cell
Signaling (Cat # 2062, 57156, 85057 and 20458). HDAC6 antibody was purchased from
Abclonal (Cat # A11259). HDAC8 and HDAC11 antibodies were a kind gift from Dr. Ed
Seto (George Washington University). All primary antibodies were diluted 1:1,000 in
blocking solution + 0.1% Tween-20, and incubated overnight at 4°C. Actin (Santa Cruz
sc-1615 or Cell Signaling #3700) was used as a loading control. Blots were washed,
then

incubated

with

HRP-conjugated

anti-species

secondary

(Cell

Signaling

Technology, Rabbit #7074/Mouse #7076, 1:1,000) and developed by enhanced
chemiluminescence followed by exposure to light-sensitive film or imaging by LI-COR
Odyssey Fc. Quantification performed with Image Studio software (LI-COR).
For HDAC1, HDAC2, and HDAC5 silencing, siRNA was purchased from Santa
Cruz (Cat # sc-29344, sc29346, sc-35542, control siRNA sc-37007). HDAC6 siRNA
was purchased from Dharmacon (Cat # L-043456-02-005). siRNA transfections were
performed using Lipofectamine RNAiMAX Cat # 13778030) according to manufacturer
protocols.
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Cytotoxicity assays:
SAOS2, SAOS2 LM7 and K7M2 cells were seeded 5X103 cells per well in 96-well plates
in triplicate and were treated with a dose range of panobinostat (Selleckchem Cat
#S1030) (1.8, 2.4, 3.3, 4.5, 6.0, 8.1, 11.0, 14.8 and 20nM) or a dose range of
romidepsin (Selleckchem Cat #S3020) (5.9, 8.8 13.2, 19.8, 29.6, 44.4, 66.7, 100 and
150nM). For dual treatment with Panobinostat and Carfilzomib (Selleck Cat #S2853)
K7M2 and SAOS2 cells were plated at 5X103 cells per well in 96-well plates and treated
with panobinostat at a dose range (1.4, 1.8, 2.5, 3.3, 4.5, 6.1, 8.2, 11.1 and 15nM) or
carfilzomib at a dose range (1.9, 2.6, 3.5, 4.7, 6.3, 8.5, 11.5, 15.6 and 21nM) or
combination of both drugs. IC50 values were determined at 48 hours post treatment
using Cell Titer Blue assay (Promega, Cat # G8080) To determine the tubastatin
(Selleckchem Cat # S2627) IC50 value K7M2 cells were seeded at 2X104 per well in 96well plates and treated with the following concentrations (0, 1, 5, 10, 15, 100, 250, 500,
1,250, 2,500, 5,000,and 10,000 nM). All treatments were done in triplicate and cell
growth was assayed at 48 hours using MTS Cell Titer 96-well proliferation assay
(Promega Cat # G5421). The impact of panobinostat and romidepsin on PDX derived
cell

lines

was

examined

in

a

publicly

available

dataset

(https://braid.stjude.org/masttour/) [123].
In vivo studies:
All in vivo studies were performed under the Moffitt/University of South Florida Institute
of Animal Care and Use Committee approved protocol R3540 (CCL). For in vivo
experiments K7M2 or SAOS2-LM7 luciferase-expressing cells were injected into BalB/c
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or NSG mice, respectively.

For the primary osteosarcoma study 1X105 cells were

injected intratibially in 20µl of sterile PBS into one of the hind tibias. The other hind tibia
was injected with 20µl of sterile PBS as a control. For the lung seeding studies 1X106
K7M2 cells were injected intravenously via tail vein. For treatment with panobinostat
(10mg/kg in 10mM Citrate buffer with 10% Captisol, (Cydex pharmaceuticals, Cat # RcOC7-100) mice were randomized into cohorts for treatment by intraperitoneal injections
in 200-μl volumes of either panobinostat or vehicle for the remainder of the study (5
days on, 2 days off treatment).

Treatments with romidepsin 2.4mg/kg dissolved in

2%DMSO, 30% 400PEG, 5% Tween 80 in ddH20 were administered twice a week
subcutaneously in 100-μl volumes. Treatment with Carfilzomib (2mg/kg in 10mM Citrate
buffer with 10% Captisol) was administered by tail vein injection in 100-µl volumes on 2
consecutive days followed by 5 days no treatment. In the dual panobinostat carfilzomib
treated mice group we treated with 1/10 of the dose of the individual drugs (0.2mg/kg
carfilzomib and 1mg/kg panobinostat). Each week, mice received both carfilzomib and
panobinostat on days 1 and 2 followed by three days of panobinostat only and then two
days no treatment. Bioluminescence for all studies was measured as a correlate of
tumor growth (IVISTM, Perkin Elmer).
Ex vivo bone analysis:
Tibias were collected and fixed in 10% formalin for 24-48 hours then transferred to 50%
ethanol. Radiographic images (Faxitron, X-ray Corp) were obtained using energy of
35kVp and an exposure time of 8 milliseconds. The spatial resolution is 10 lp/mm
(48μm). The tumor volume (TuV) was calculated as a function of the total tissue volume
(TV) of the tibial medullary canal using ImageJ software. For μCT analysis, the proximal
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tibia metaphyses were scanned (μCT-40; Scanco Medical). An evaluation of trabecular
bone structural parameters was performed in a region that consisted of 1mm starting at
500μm from the growth plate. A three-dimensional cubical voxel model of bone was
built, and calculations were made for relative bone volume per total volume and
trabecular number. After X-ray and µCT analysis, tibias were decalcified (14% EDTA,
pH 7.4, 3 weeks), processed, and paraffin embedded.

Immunofluorescence:
For paraffin embedded tissues, slides were dewaxed and rehydrated to water. Antigen
retrieval was performed with heat 5 minutes in a pressure cooker (1X Tris EDTA pH 9).
Slides were blocked in 10% goat serum in 1X TBS for 1 hour at room temperature.
Primary antibodies Phospho-Histone H3, Cell Signaling Cat #9701L, 1:400 dilution;
Cleaved Caspase 3 1:200 dilution, Cell Signaling Cat #9661S, were diluted in 10%
normal goat serum (Vector Laboratories Cat # S-1000) and incubated overnight at 4ᵒC
in a humidified chamber. After 3 washes in 1X TBST followed by 1 wash in 1X TBS,
secondary antibodies (Alexa FluorTM Goat Anti Rabbit 568, (Thermo Fisher Scientific
#A-11011); Alexa Fluor Goat Anti Mouse 488, (Thermo Fisher Scientific #A32723) were
incubated at a 1:1,000 dilution in 10% normal goat serum for 1 hour at room
temperature. Slides were washed three times in 1X TBS and mounted using
Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories, # H-1200).
Slides stored under light-proof conditions until image acquisition.
For in vitro immunofluorescent analyses, cells were seeded into 8-well chamber
slides (LAB-TEK #154534) at 2x104 and cultured overnight before treatment with either
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50% MSC CM or DMEM 5% FBS or 100nM etoposide for 5 hours. Cells were then
rinsed with PBS and fixed in 4% PFA at room temperature for 20 minutes. Fixed cells
were then blocked for 30 minutes at room temperature in antibody diluting buffer (2%
BSA, 0.1% Triton X-100 in PBS). Primary antibodies (Acetyl-Histone H3, Millipore #06599, 1:400 dilution in antibody diluting buffer; Rabbit IgG Isotype Control, Thermo
Scientific #31235) were incubated at room temperature for 30 minutes. Cells were then
washed 3x in PBS and incubated with secondary antibody (Alexa FluorTM Goat AntiRabbit 488, Invitrogen #A-11034, 1:1000 dilution in antibody diluting buffer) for 30
minutes at room temp in the dark. After washing 3x in PBS, culture chambers were
removed, and the slides were mounted with Vectashield Antifade Mounting Medium with
DAPI (Vector Laboratories, # H-1200). Mounted slides were stored under light-proof
conditions at 4ᵒC until microscopic analysis.

For quantitation of immunofluorescent

stained samples, 3 representative images were acquired at 40X magnification, and the
ratio of positive stained cells to total number of cells per field (using DAPI) were
calculated using ImageJ.
Statistical analysis:
To determine statistical significance among groups, T-test or analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test was performed. A p-value <0.05
was considered as statistically significant. Data are presented as standard error from
the mean (S.E.M). All statistical analyses were performed with Graph Pad Prism 6.0
(GraphPad Inc. La Jolla, CA).
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Chapter 4: Metastatic Skeletal Malignancy and Prostate Cancer:
Introduction:
Metastasis marks a turning point for many cancers, evolving from a disease that can
generally be successfully treated to one for which cure is unlikely with present
therapies. This is due in part to the indispensable nature of the organs involved. The
skeleton is one of the most common sites of metastasis, with prostate and breast
cancer comprising nearly 70% of all cases [132-135]. Lung, kidney, thyroid, bladder,
melanoma, and renal cell carcinoma can also metastasize to the bone. Bone
metastases are currently incurable and extremely painful.

Most currently available

therapies are palliative and fail to increase overall survival.
The bone microenvironment is comprised of many different cell types including
hematopoietic cells, stromal cells (e.g. fibroblasts and mesenchymal stem cells),
endothelial cells, adipocytes, chondrocytes, osteoblasts, and osteoclasts [136].
Understanding

the

roles

and

interaction

of

these

cell

types

in

the

bone

microenvironment and tumor cells can provide key insights into new therapeutic options
for patients with bone metastases.

Prostate Cancer Overview:
The prostate is an organ that is part of the male reproductive system. Normally the size
of a golf ball, its main function is to secrete fluid that protects the sperm during
ejaculation.

As men age; the prostate commonly grows larger in size, a condition
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diagnosed as benign prostatic hyperplasia (BPH) [137]. Although BPH is not cancer, it
can result in some of the same symptoms such as frequent need to urinate and difficulty
urinating. Prostatic intraepithelial neoplasia (PIN), is a precancerous condition defined
by the presence of abnormal prostate cells that can be categorized as either low or high
grade. Men with high grade PIN are more likely to develop prostate cancer [138, 139].
Initially, prostate cancer is localized to the prostate gland, but as it progresses to
advanced prostate adenocarcinoma, there is often local invasion. If left untreated, the
cancer can become metastatic and spread to distant sites, commonly the lymph nodes
and skeleton.
Prostate cancer stage is defined by histological analysis of biopsies using a
numeric grading scale defined by Donald Gleason in the 1970s and refined several
times since [140] [141, 142]. The score is calculated by assigning a value between 1-5
based on the abnormality of the tissue with 5 being the most abnormal. There are two
scores given by analyzing the 2 biggest tumor sections found in the microscopic
analysis of a biopsy. The two scores are added together for a final score. Gleason
score prognosis is defined using the International Society of Urological Pathology
(ISUP) grading system shown in (Table 3) [143].
One of the defining features of prostate cancer are hormones. Specifically,
androgens such as testosterone drive the growth of this cancer.

The discovery of

hormone ablation as a treatment for prostate cancer lead to a Nobel prize for Charles
Brenton Huggins [144]. Castration or androgen deprivation therapy is a valuable therapy
for advanced prostate cancer patients still used today, however in almost all cases, the
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cancer eventually progresses in the absence of androgen and becomes known as
castrate resistant prostate cancer (CRPC) [145].

Table 3: Table of (ISUP) grading system and prognostic risk in relation to Gleason
Score [143]

Prostate Cancer Statistics:
Prostate cancer is the 2nd most diagnosed cancer in men with approximately 165,000
new cases diagnosed and almost 30,000 deaths estimated in 2020.

To put these

numbers into a different perspective, 1 in 9 men will be diagnosed with prostate cancer
in his lifetime, and 1 in 41 will die from prostate cancer [146]. If prostate cancer is
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diagnosed before metastasis, the 5-year survival rate is approximately 99% but once
the cancer spreads to a distant site, the survival rate decreases to 30% [147]. The most
common site for prostate cancer metastasis is the skeleton, but other sites can include
lymph nodes, lungs, liver ,brain, and less commonly to adrenal glands, breasts, eyes,
kidneys muscles, pancreas, salivary glands and spleen [146]. In a study that analyzed
1,589 autopsies of men with advanced prostate cancer, 90% had evidence of bone
metastases [148]. Since bone is the most common site of prostate metastasis, our
studies focus on understanding the skeleton as a metastatic site for prostate cancer.
Prostate Cancer Risk Factors:
Some common risk factors for prostate cancer include age, race, genetics, exposure to
radiation, smoking, and obesity [149]. The average age of prostate cancer at 66 has
decreased since prostate specific antigen (PSA) screening for prostate cancer became
common. PSA is a serine protease that is produced by prostate epithelial cells and
prostate cancer cells. Rising serum PSA levels in serum can indicate prostate cancer
progression, but there is controversy regarding the reliability of PSA and improved
biomarkers are urgently needed [150, 151]. Age is a primary risk factor for prostate
cancer, with only 10% men diagnosed in 2012 under the age of 55. [152, 153]. African
American men are more than 60% more likely to develop prostate cancer compared to
Caucasian men. [154]. Having a family history of prostate cancer is a risk factor [155,
156]. Environmental and behavioral factors are also implicated. Chemical and radiation
exposure increase the risk of developing many types of cancer, and radiation therapy
for prostate cancer in some cases is the cause of second primary cancer formation
[157, 158]. Smoking is generally associated with increased risk for lung cancer but

54

increases the risk of many cancer types including prostate cancer [159]. Obesity is a
risk factor for many diseases including prostate cancer. For example, greater body
mass index (BMI) is correlated with a significant higher risk of prostate cancer mortality
[160].

Conflicting literature suggests it is possible that increased height may also

increases the risk of developing prostate cancer [161, 162].
Prostate Cancer Genomics:
The most notable genomic abnormality in prostate cancer is the gene fusion of
transmembrane protease serine 2 (TMPRSS2) and members of the E26 transformationspecific (ETS) transcription factors [163]. The ETS transcription factors are a group of
29 different genes divided into 12 subgroups that share common DNA binding domains
or ETS domains [164, 165]. These transcription factors are important in regulating
many

cellular

processes

including

apoptosis,

cell

proliferation,

differentiation,

angiogenesis and metastasis [166]. The most common ETS gene found overexpressed
in nearly 50% of prostate cancers is the oncogene ETS-related gene (ERG) [167]. The
fusion with androgen regulated TMPRSS2 is frequently responsible for the
overexpression of ERG [163]. The TMPRSS2/ERG fusion commonly leads to
overexpression of the oncogene c-MYC (MYC) [168].

Genetic alterations in the

chromosomal location of the androgen receptor (AR), Xq11-12 are also common in
prostate cancer patients.

Sequencing of 50 samples obtained from treated CRPC

patients after rapid autopsy confirmed a list of genes that have been reported to be
mutated in prostate cancer. The genes included TP53, PTEN, APC, ZFHX3, and RB1
[169].
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Current Therapies for Prostate Cancer:
Treatment for prostate cancer is dependent on the disease stage, age, and health of the
patient. Early stage prostate cancer that is localized and has a Gleason score of 6 or
below is often monitored with active surveillance or watchful waiting.

It often can be

years before progression of tumor growth requires any treatment, and side effects of
treatments include erectile dysfunction and incontinence which negatively affect quality
of life. Since most men are elderly when diagnosed with prostate cancer, many men do
not undergo treatment and instead elect for active surveillance [170-172]. When a
patient’s Gleason score indicates high-risk prostate cancer, the recommended therapy
is typically surgery (radical prostatectomy) followed by radiation therapy and ADT;
chemotherapies are sometimes co-administered with ADT commonly if other therapies
fail [146, 173]. Radiation therapy options for prostate cancer include external beam
radiation (EBRT) and brachytherapy. EBRT when the prostate is targeted with beams of
radiation. There are multiple different options for ERBT they include three-dimensional
conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT),
stereotactic body radiation therapy (SBRT), and proton beam radiation therapy [174].
Brachytherapy or internal radiation therapy is when small radioactive pellets are
inserted directly into the prostate. In high-risk cases, brachytherapy can be combined
with EBRT [175].
ADT or hormone therapy is used to block the male sex hormone testosterone
from activating AR signaling that fuels prostate cancer cell growth. AR is a nuclear
hormone receptor, which serves as a transcription factor that regulates gene expression
responsible for the formation of the male reproductive system, including the prostate
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[176]. AR is activated and translocated to the nucleus by the binding of its ligands
androgens. Androgens are androstenedione, testosterone and dihydrotestosterone
(DHT) [177]. Androstenedione is a testosterone precursor, and testosterone is
converted to the biologically active DHT by 5a reductase which has a 2-fold higher
binding affinity to AR [178]. Testosterone production begins when chemicals in the
brain stimulate testosterone production in the testes.

When the body detects low

testosterone levels, the hypothalamus begins producing luteinizing hormone-releasing
hormone (LHRH) that stimulates luteinizing hormone (LH) production by the pituitary
gland. LH then stimulates production of testosterone by the testes [179].

The most

radical form of ADT is orchiectomy or surgical removal of the testes this is irreversible
but is also cost effective compared to other treatments [180].

There are

pharmaceutical approaches that can be administer in lieu of the surgical route, including
chemical castration or antiandrogen therapy. There are LHRH agonists and antagonists
that both block the production of testosterone, these drugs include leuprolide, goserelin,
triptorelin, histrelin, and degarelix.

Anti-androgen drugs such as bicalutamide,

nilutamide and flutamide block the testosterone function by binding and blocking AR.
These drugs are often administered in combination with LHRH agonists [181].
Unfortunately, ADT therapy generally fails within 1-3 years, at which point the
disease progresses to a hormone refractory state known as CRPC. There are multiple
mechanisms by which PCa becomes castrate resistant. Many of these involve changes
to the androgen receptor, including amplification, mutation, or expression of splice
variants leading to constitutive activation [182] [183, 184]. AR amplification is observed
in approximately 80% of patients [185]. Mutations in the ligand-binding regions of AR
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causes AR antagonists, such as flutamide, bicalutamide and enzalutamide that typically
work by binding AR and blocking the binding of androgens, to act as agonists activating
AR and promoting prostate cancer progression [186-189]. Other signaling pathways
can also become hyperactive following androgen deprivation therapy. In approximately
40% of primary prostate cancer, PI3K/AKT signaling pathway is altered, whereas it is
altered in almost 100% of metastatic CRPC [190]. Amplification of c-Myc also occurs in
approximately 70% of patients after ADT [191]. Consequently, metastatic disease must
be targeted differently from the original primary cancer.
The treatment strategies for CRPC often includes chemotherapy. According to
the National Comprehensive Cancer Network (NCCN) the most common chemotherapy
used for advanced prostate cancer is docetaxel. Patients that do not respond to
docetaxel can be given cabazitaxel, but at the risk of severe side effects. Mitoxantrone
hydrochloride, is another chemotherapeutic option [146, 192]. Second generation ADT
therapies are also available to CRPC patients. Abiraterone is an anti-androgen drug
that can be effective in treating CRPC by inhibiting the cytochrome p450 enzyme 17Rhydroxylase17,20-lyase (CYP17A1), an enzyme needed for the production of
androgens. In 2011 abiraterone was FDA approved for the treatment of CRPC [193,
194]. Another anti-androgen drug FDA approved in 2012 for CRPC patients is
enzalutamide. Enzalutamide can block AR from translocation into the nucleus as well
as prevent DNA binding of AR [195]. Another option for CRPC patients is a dendritic
cell vaccine, sipuleucel-T.

Currently sipuleucel-T is the only FDA approved

immunotherapy available for prostate cancer receiving approval in 2010 [196].
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Therapies for bone metastatic prostate cancer are mainly palliative with the
exception of radium 223. Radium 223 is a calcium mimetic with the ability to bind
hydroxyapatite, and therefore, targets areas of the skeleton where bone is actively
being remodeled. It simultaneously emits alpha particles that cause irreversible double
strand DNA breaks [197] . The FDA-approved radium 223 for bone metastatic CRPC in
2013 after it was shown to increase median overall survival form 11.2 months to 14
months [198, 199]. Most therapies for bone metastatic patients aim to prevent bone
destruction by targeting osteoclasts.
denosumab.

These drugs include bisphosphonates and

Bisphosphonates, as the name suggests are a group of chemical

compounds consisting of two phosphate groups, they are derived from modifications to
inorganic pyrophosphate (PPi). In the 1960s PPi was found to bind hydroxyapatite
crystals and inhibit calcification [200]. Bisphosphonates are recruited to areas of active
bone remodeling, where they are taken up by bone-resorbing osteoclasts, leading to
their apoptosis [201]. There is also evidence that bisphosphonates can protect against
pathological bone fracture by promoting survival of osteoblasts and osteocytes [202].
Receptor activator of nuclear factor-κB ligand (RANKL) is produced by osteoblasts and
binds the RANK receptor on osteoclast precursors and promotes the formation of
mature bone resorbing osteoclasts. Denosumab is a monoclonal antibody that binds
RANKL and inhibits the binding to RANK on osteoclast precursors. This reduces
osteoclast formation and activity [203, 204]. Denosumab does not increase overall
survival of bone metastatic prostate cancers but does reduce skeletal related events
(SRE) reduces bone pain and increases quality of life. The current treatments for bone
metastatic prostate cancer are limited and mainly palliative with the exception of a slight
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survival increase with the use of Radium 223. Understanding and further exploiting the
interactions of the cancer cells and the bone microenvironment may lead to new
therapeutics that are desperately needed.
Vicious Cycle of Bone Metastasis:
The vicious cycle is a paradigm that describes the symbiotic relationships between the
bone microenvironment and the tumor cells that metastasize to the bone. A simplistic
explanation of the vicious cycle includes three main cell types osteoblasts, osteoclasts
and tumor cells. Osteoblasts are the cells that produce new bone, when mature they
secrete extracellular matrix consisting of alkaline phosphatase, osteocalcin and type 1
collagen; this matrix is also known as the osteoid. The osteoid is then mineralized into
hardened bone by hydroxyapatite [205]. Osteoclasts are the cells that degrade bone.
Mature multinucleated osteoclasts from a seal with their “ruffled membrane” with the
bone surface they then secrete hydrochloric acid and proteases most notable Cathepsin
K, which demineralizes the bone. The osteoclast endocytoses the demineralized bone
and factors trapped in the bone, and it is secreted though its apical surface [206, 207].
The third cell type is the tumor cell.

When the tumor cells establish in the bone

microenvironment, they secrete growth factors and cytokines such as VEGF, PDGF,
ET-1, BMPs, PTHrP, various interleukins and other molecules. The osteoblast
precursors MSCs are stimulated and differentiate into mature activated osteoblasts.
[208] . These osteoblasts express RANKL and macrophage-colony stimulating factor
(M-CSF). The RANKL binds RANK and M_CSF binds c-fms on osteoclast precursor
cells, monocytes.

Under this stimulation by osteoblasts the monocytes fuse and

become multinucleated osteoclasts. As the osteoclasts degrade bone they release
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many different growth factors that are trapped in the bone matrix such as, TGF-βB,
IGFs, Ca+, and other factors that feedback and fuel the growth and survival of the tumor
cells completing the cycle [209]. Those 3 cell types are commonly used to describe the
vicious cycle but there are many other cells in the bone marrow microenvironment that
are also involved. They include but not limited to hematopoietic stem cells (HSCs),
mesenchymal stem cells (MSCs) endothelial cells, macrophages and MDSCs [210].
Understanding how to interrupt this cycle could provide therapeutic options to treat and
cure bone metastases.
HSCs reside in the bone marrow and are the cells that give rise to all of the
different blood and immune cells [211]. The HSC niche is located on endosteal regions
in close proximity to the locations where osteoblasts reside. The survival, quiescence
and proliferation of HSCs is regulated by osteoblasts produced cytokines [212-214].
MSCs are the precursors to the bone forming osteoblasts and also secrete many
different cytokines and chemokines into the bone microenvironment.

For example,

MSC-induced tumor derived lysyl oxidase (LOX) promotes breast cancer metastasis
[215]. MSCs also secrete VEGF, promoting angiogenesis and metastasis [216].
The vasculature plays important roles in bone metastasis, including promoting
tumor cell dormancy. Dormancy is a challenging clinical aspect of metastatic disease,
as disseminated tumor cells can remain undetected in protective niches until they
awaken years, sometimes decades, later to form macrometastases [217, 218]
Endothelial cells produce thrombospondin-1 that promotes the dormancy of breast
cancer cells [219]. Osteoblasts also contribute to dormancy in the bone by production of
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growth arrest specific 6 (GAS6) that when binds with its receptor AXL on disseminated
prostate cancer cells triggering TGFb2 signaling. [220, 221].
It is becoming increasingly evident that immune cells are involved in the vicious
cycle [210]. Macrophages present in the bone marrow can play important roles in tumor
progression and fueling the vicious cycle. Macrophages can be both pro- and antitumor and are can be classified as either M1 or M2 phenotypes.

Anti-tumor M1

macrophages create an inflammatory environment by producing cytokines such as
interleukin 1 (IL-1) interleukin-9 (IL-9) and tumor necrosis factor (TNF).

They also

produce nitric oxide (NO) and reactive oxygen intermediates (NOI) that can cause tumor
apoptosis [222].

M2 macrophages produce anti-inflammatory cytokines such as

interleukin 10 (Il-10) CCL17 and CCl18. and have pro-tumor roles [223]. Tumor cells
produce chemokines such as CCL2, M-CSF, and VEGF that recruits macrophages into
the tumor microenvironment. These macrophages are referred to as tumor-associated
macrophages (TAMs). Due to other factors produced by the tumors such as IL10, IL-4
and IL-13 TAMs become polarized to the M2 phenotype [224]. Macrophage precursors,
monocytes that reside in the bone marrow can also become myeloid derived suppressor
cells (MDSCs). MDSCs can suppress T-cell activation and promote tumor growth and
metastasis.

They also have direct roles in the vicious cycle due to their ability to

differentiate into osteoclasts [225]. MDSCs produce large quantities of TGF-β, which
induces PTHrP production by tumor cells, this

reestablishes the vicious cycle with

stimulation of osteoblast derived RANKL [226].
Halting the vicious cycle will require careful study of the factors and cell types
involved in regulating disease progression. It is presently unclear why prostate-bone
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metastases tend to be osteogenic, whereas other cancers such as breast produce
osteolytic metastases. Factors produced by primary prostate cancer cells in the vicious
cycle such as WNTs, bone morphogenic proteins (BMPs), fibroblast growth factors
(FGFs) insulin-like growth factors (IGFs) have profound effects on MSC and osteoblast
biology and are likely to play a role in the formation of osteogenic lesions [227-230].
Mesenchymal Stem Cells:
MSCs are pluripotent cells that can reside in almost every tissue in the body, having
been isolated from many different tissue types, including bone marrow, cortical bone,
amniotic fluid, adipose tissue, fetal tissues, dental pulp, and umbilical cord. [231-236]
[237]. The bone marrow is an especially rich reservoir for these cells, where they
account for approximately 1 out of every 10,000 bone marrow cells [238]. MSCs have
the ability to differentiate under appropriate stimulus toward several lineages, including
chondrocytes (cartilage), adipocytes (fat) and osteoblasts (bone) [239]. There is also
evidence that they can form non-mesenchymal tissue such as gut, lung, liver and skin
epithelium [240-243]. There is still debate on whether the cells that can differentiate into
non mesenchymal tissues are mesenchymal stem cells or if the origin of these tissues is
actually another population of multipotent adult progenitor cells. [241] MSCs are
recruited to wound sites, where they play an active role in repairing damaged tissue
[244, 245]. There are many cellular markers for MSCs, however many are not exclusive
and can differ depending on the source of the MSCs. Human MSCs do not express
hematopoietic markers and are generally negative for CD45, CD34, and CD14. The
following markers are generally accepted as markers that are expressed by MSCs:
CD105, CD73, CD44, CD90, Stro-1 and CD29 [240, 246-248].
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MSCs and Their Dynamic Roles in Cancer Progression:
The idea that cancer is a disease of chronic inflammation was proposed in 1858 by
Rudolph Virchow [249]. Since that observation, cancer has been described as wounds
that do not heal [250]. MSCs are attracted to sites of inflammation and consequently
are also attracted to the sites of tumors [251, 252]. There is conflicting information as to
whether MSCs promote or inhibit tumor growth, and this seems to depend on the stage
of cancer progression and tissue context. [253, 254] MSCs are pro-tumorigenic in
many different cancers including breast, osteosarcoma, melanoma, lung, prostate and
colon [255-262], and this occurs by multiple mechanisms. It is well documented that
MSCs can differentiate into carcinoma associated fibroblasts (CAFs) and secrete tumor
promotive growth factors such as stromal derived factor-1 (SDF-1) [263-265]. MSCs
can also suppress immune cells as part of their wound healing activities, contributing to
the pro tumor effects of MSCs.

For example, in an allogeneic model where B-16

melanoma cells were implanted with or without MSCs, tumors only formed in the
presence of MSCs, demonstrating the immune suppressive pro-tumorigenic effects of
MSCs [258].

MSCs suppress the immune system by secretion of factors such as

prostaglandin E2 (PGE2), interleukin 6 (IL-6), IL-10, and indoleamine 2,3 deoxygenase
(IDO) [266-270]. MSCs can also promote tumor vascularization by secretion of proangiogenic factors such as VEGF and FGF-2 [216]. In colorectal cancer, MSC-derived
neuroregulin 1 (NRG1) activates HER2/3 and AKT signaling to promote cancer cell
survival [271]. Further, MSCs can promote metastasis by secretion of factors such as
PDGF and TGFb which in turn activate EMT and promote transcription factors in tumor
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cells like Snail, Slug and TWIST [272, 273]. For example, when breast cancer cells are
co-cultured with MSCs epithelial genes become downregulated and EMT associated
genes are upregulated [274]. MSCs suppress apoptosis through the upregulation of B
cell lymphoma 2 (BCL2), by secretion of VEGF and FGF-2 [275, 276].

Multiple

chemokines and cytokines secreted by MSCs can be pro-tumorigenic. For example,
MSCs recruited to the breast cancer microenvironment secrete chemokine ligand 5
(CCL5) that promotes cancer cell invasion and metastasis [255]. In hepatocellular
carcinoma, MSC-derived interleukin 6 (IL-6) promotes the progression promotes cancer
progression via activation of STAT3 [271, 277].

MSCs have also been shown to

promote osteosarcoma by activation of STAT3 leading to drug resistance [257].
Many studies have reported anti-tumorigenic effects of MSCs in various cancer
types as well, including some that have also shown pro-tumorigenic effects, such as
Kaposi’s sarcoma, liver, breast, pancreatic, lung, melanoma, glioma, non-Hodgkin’s
lymphoma and multiple myeloma [278-286]. In an in vivo model of Kaposi’s sarcoma,
human MSCs injected intravenously inhibited tumor growth by downregulation of AKT
signaling in the tumor cells

[278].

Wnt-signaling has also been shown to be

downregulated by MSCs. For example, breast cancer cell growth was inhibited by
MSC-derived DKK-1 which downregulated Wnt signaling [280]. Human MSCs were
also shown to inhibit the growth of liver cancer cell lines both in vitro and in vivo,
increasing apoptosis and decreasing proliferation by downregulating anti apoptotic
factors like Bcl-2 survivin, and c-Myc [279]. Adipose derived MSCs inhibited pancreatic
cancer growth both in vitro and in vivo by inducing cell cycle arrest but not apoptosis
[281]. MSCs express the pro-apoptotic factor fas ligand (FasL) that normally promotes
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wound healing by promoting the apoptosis of T-cells [287]. MSC derived FasL has
been shown to trigger multiple myeloma cell apoptosis both in vitro and in vivo [286].
The effects MSCs have on tumorigenesis can also be dynamic, where for
example they impair progression during the initial stages of hepatocarcinoma but
support later stages of the disease [288]. The opposing effects of MSCs on tumor
progression may in part be explained by the tissue source. Specifically, MSCs can be
derived from several sources – bone marrow, umbilical cord blood, peripheral blood,
dental pulp and adipose tissue – and MSCs from each tissue source differ in their
capacity to either promote or inhibit cancer growth [289].
MSCs and Prostate Cancer:
MSCs have been shown to promote the metastasis of primary prostate cancer.
Prostate cancer cells express the cytokine chemokine (C-X-C motif) ligand 16
(CXCL16), which recruits MSCs that express C-X-C chemokine receptor type 6
(CXCR6) or CD168.

The CXCL16/CXCR6 signaling cascade leads to the

transformation of MSCs into cancer associated fibroblasts (CAFs) that express C-X-C
motif chemokine 12 (CXCL12) also known as stromal cell-derived factor 1 (SDF-1). The
CXCL12 expressed by CAFs binds to CXCR4 on tumor cells promoting EMT and
metastasis. [263] This work provides insight into the role of MSCs in primary prostate
cancer, however the roles of MSCs on bone metastatic prostate cancer are still not fully
understood.
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Chapter 5: Mesenchymal Stem Cell-Derived Interleukin-28 Can Drive the
Selection of Apoptosis Resistant Bone Metastatic Prostate Cancer

Rationale:
Bone metastatic prostate cancer promotes mesenchymal stem cell recruitment and their
differentiation into osteoblasts. However, the effects of bone-marrow derived MSCs on
prostate cancer cells are less explored. Here, we explore the effects of those
interactions. We and others have reasoned that defining how prostate cancer cells
establish and grow in the bone microenvironment may reveal new therapeutic targets
for treatment [135, 290, 291]. We aim to understand how MSCs promote the evolution
of prostate cancer cells in bone microenvironment through secretion of IL-28 and
activation of Janus kinase/signal transducers and activators of transcription (JAK/STAT)
signaling pathway in prostate cancer cells.
Interleukin 28 (IL-28) also known as interferon l (IFN l) is a cytokine that was
discovered in 2003 [292, 293]. IL-28 is induced by viral infection and is secreted by
both macrophages and dendritic cells to exert anti-viral activity [294].

IL-28 has 2

isoforms IL-28A and IL-28B that are 96% homologous. Both isoforms have a similar
amino acid sequence to interleukin 29 (IL-29) [292]. Together, these 3 interleukins
make up the type III interferon family and are clustered together on human chromosome
19 or murine chromosome 7 [295]. IL-28 signals through a heterodimer receptor made
up of IL-28Ra and IL-10Rb [296].
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The JAK/STAT pathway is activated by IL-28 binding its receptor allowing JAK1
and TYK2 to bind the cytoplasmic ends of the receptor complex and activate latent
STATs 1, 2, 3 and 5. [297] Since its discovery, IL-28 has been shown to have multiple
different functions including anti-tumor activities [298-300]. Other cytokines and growth
factors can activate the signaling pathway.

Depending on the ligand binding, the

receptors can form homodimers, heterodimers, or trimers. These receptor complexes
can then become activated by JAKs that cross phosphorylate each other and
phosphorylate of the C-terminus of the receptor complex. There are four different JAKs,
JAK1, JAK2, JAK3 and Tyk2 that are selective for specific receptors. Originally JAK1
and JAK2 were discovered by a PCR screen from protein kinases and were called “just
another kinase” but were renamed Janus kinase after the 2 faced Roman god because
of the two phosphate transferring domains that play opposite roles in the kinase activity
of the proteins [301].
STATs have SRC homology 2 (SH2) domains that can bind phosphorylated receptor
complexes where they are phosphorylated and allow the production of either
homodimers or heterodimers with other STAT members. There are STAT inhibitors that
disrupt the SH2 domain and inhibit STATs from dimerizing and acting as transcription
factors [302]. Seven different STATs that have been discovered, STAT1, STAT2,
STAT3, STAT4, STAT5a, STAT5b and STAT6 [303].

Once phosphorylated and

dimerized STATs translocate to the nucleus where they directly bind DNA and regulate
gene expression. [304-308]. The JAK/STAT pathway has normal roles in regulation of
inflammation and apoptosis, the dysregulation of the pathway can result in diseases of
the immune system and cancer. STAT3 has been implicated in cancer progression and
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metastasis and has been described as an oncogene [309, 310]. In one study, 95% of
223 prostate bone metastasis samples were positive for pSTAT3. We propose that
using a small molecule STAT inhibitor, we can treat bone metastatic prostate cancer.

RESULTS:
MSCs have dynamic effects on prostate cancer cell growth:
Human [311] and mouse bone metastatic prostate cancer specimens were initially
assessed for MSC content by immunohistochemistry (IHC). As predicted [312, 313],
there were abundant numbers of α-SMA positive MSCs in both human and mouse bone
metastatic prostate cancer (Fig. 13a). These findings were confirmed using additional
markers for human (CD90) and mouse (nestin) MSCs (Figure 17) [313-315]. To assess
the possible effects of MSCs on prostate cancer cells we isolated mouse bone MSCs
(CD29+SCA1+CD45Neg) and confirmed their stemness properties by performing
osteoblastic, adipogenic and chondrogenic differentiation assays (Figure 20). Using a
modified Boyden chamber assay, we observed MSCs are highly chemotactic to prostate
cancer cell line-derived conditioned media compared to serum-free control (Figure 19
b). To assess the potential effects of MSCs on prostate cancer cell fate, the rodent
prostate cancer cell line PAIII [316, 317] was directly co-cultured with mouse MSCs.
Notably, MSCs significantly inhibited prostate cancer cell growth even down to 1:10
ratios of MSC to PAIII cells (Figure 19 c). Further, a dose-dependent inhibition of
prostate cancer cell growth was evident when they were cultured with MSC conditioned
media (CM); thus, a soluble MSC-derived factor suppresses prostate cancer cell growth
(Figure 19 d). A significant rounding of PCa cells combined with detachment was noted
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within 6 hours of culture with CM, suggesting that the MSCs triggered PCa cell
apoptosis. Consistent with this, high levels of cleaved caspase-3 are manifest in MSC
CM-treated PCa cells compared to controls within 6 hours (Figure 19 e). This effect was
not limited to PAIII PCa cells or to mouse MSC, as both mouse and human MSC
conditioned medium impaired the growth of mouse Myc-CAP and human RWPE and
DU145 prostate cancer cells (Figure 19 f). By contrast, culture in MSC CM increased
the growth rates of V-CAP, 22RV1, LNCaP and the LNCaP derived C4-2B prostate
cancer cell lines compared to controls, underscoring the complexity of MSC effects on
prostate cancer cell behavior (Figure 19 f). Of note, the negative effects on prostate
cancer cell growth were MSC-specific, as conditioned medium derived from osteoblasts
failed to affect PCa cell growth (Figure 19 g). Finally, MSC CM also did not affect the
growth of normal prostate epithelial cells (PREC; Figure 19 h).
Prostate cancer conditioned media promotes osteogenesis of MSCs:
Prostate cancer has a unique phenotype when it metastasizes to the bone. Whereas
most cancers that metastasize to the bone, such as breast and lung cancers, produce
osteolytic lesions and loss of bone mass, prostate cancer typically produces mixed
lesions with both osteosclerotic and osteolytic lesions. To determine if secreted factors
from prostate cancer cells is responsible for the increased bone formation commonly
observed in prostate to bone metastases MSC were differentiated in the presence or
absence of conditioned media from prostate cancer cells. Conditioned media from
prostate cancer cell lines was used in combination of osteogenic supplements to assess
the effect of osteogenic differentiation.
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Figure 17: MSC infiltration in bone metastatic prostate cancer.
Representative images of CD90 staining (red; arrows) in human samples of bone metastatic prostate
(n=10; three representative patients are shown) or nestin staining (red; arrows) in tissue sections derived
from mouse tibias bearing PAIII bone metastases (three representative mice are shown). For human and
mouse specimens, pan-cytokeratin (pCK; green) was used to localize prostate cancer cells while DAPI
(blue) was used as a nuclear stain. Dashed box in merge represents area of magnification.

Conditioned media from the human bone metastatic cell line C42B and the rodent bone
metastatic PaIII cell line were collected and supplemented with complete osteogenic
supplement (OS) or to media supplemented with ascorbic acid (AA) and beta glycerol
phosphate (BGP). Conditioned media from both cell lines added to either OS or
AA/BGP supplemented media significantly increased the amount of osteogenesis in
MSCs compared to controls as measured by alizarin red staining. (Figure 21)
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Figure 18-1: Bone marrow-derived MSC effects on prostate cancer cells.
a. Representative images of α-Smooth muscle actin (SMA) staining of human and rodent bone metastatic
prostate cancer. b. MSC migration to prostate cancer cell conditioned media. Number of hematoxylin and
eosin stained MSCs per filter (MC No./Filter) were counted after 6 hours of incubation. Representative
photomicrographs of fields of view are shown. c. Direct co-culture of MSCs and PAIII prostate cancer
cells at various ratios of PAIII:MSC. Values calculated as percentage of respective PAIII controls seeded
at the same density (% Control). Growth was determined by luminescence assay and relative light unit
(RLU) measurement. d. MSC conditioned media (CM) treatment of PAIII at varying ratios. Final
concentration of serum was 10% for each condition. e. Cleaved caspase-3 (arrow head) in PAIII cells
treated for 6 hours with MSC CM (50% ratio). Arrow indicates full-length caspase-3. Etoposide (ETX;
50μM) was used as a positive control.
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Figure 19-2: Bone marrow-derived MSC effects on prostate cancer cells.
f. MSC CM (50%) effects on prostate cancer cell line growth relative to untreated controls. Growth
measurements were performed by MTT or luminescence assay. g. PAIII treated with MSC or osteoblast
(MC3T3) CM. h. Prostate epithelial cells (PREC) treated with MSC CM. MTT absorbance (ABS) was used
as a readout for cell growth. Asterisks denotes statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001,
****p≤0.0001) while NS denotes not significant.

MSCs suppress the growth of bone metastatic prostate cancer in vivo:
To examine the effects of MSCs on prostate cancer progression in bone,
immunocompromised animals were intratibially injected with luciferase-expressing PAIII
PCa cell (2x104; n=8) in the presence or absence of 1:1 ratio of mouse MSCs (2x104;
n=8) to reflect our in vitro observations. A separate cohort of mice received MSCs alone
(2x104; n=7). Contralateral limbs in each animal received sham injections that served as
an internal baseline control. We have previously shown that the PAIII PCa model
generates rapid mixed osteolytic/osteogenic responses over the course of ~15 days
prior to breaching the cortical bone [316, 318, 319]. Using bioluminescence as a
correlate of tumor growth over time, we noted that, similar to effects observed in vitro,
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PAIIII PCa growth was significantly suppressed by MSCs versus PAIII-alone cohort up
to day 11 post-transplant (Figure 23 a).

Figure 20: Characterization of mouse isolated MSCs.
MSCs were characterized using FLOW cytometry for CD29 and SCA1 positivity and CD45 negativity. The
MSCs were then differentiated into osteoblasts stained with alizarin red, adipocytes stained with oil red o
and chondrocytes stained with Alcian Blue.

However, between day 11 and 14 we observed that the growth of the PAIII cancer cells
co-injected with the MSCs rapidly accelerated (a 1,260% increase in RLU from day 11
to 14) compared to the PAIII alone cohort (166% increase in RLU over the same time
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period) rendering the differences in tumor burden insignificant by day 14 (Figure 23 b
and c).

Figure 21: Prostate cancer CM enhances osteogenesis of MSCs
MSCs were differentiated using no supplements, osteogenic supplement, or a combination of ascorbic
acid and beta glycerol phosphate. The supplements were added to either control media or media
supplemented with 50% prostate cancer conditioned media. a. PAIII CM or b. C42B CM. The amount of
differentiation after 21 days was significantly increased in the presence of the prostate cancer CM.
Asterisks denotes statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001) whereas NS
denotes not significant.

Analysis of proliferative (pHistone-H3) and apoptotic (cleaved caspase-3) indices
confirmed increased proliferation and decreased apoptosis in the PAIII+MSC cohort
with no statistical differences noted at the time of clinical endpoint compared to the
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PAIII-alone cohort (Figure 23 d, e). Analysis of MSC markers also demonstrated the
persistence of the MSCs over time in the PAIII+MSC cohort (Figure 23 f).
X-ray analyses of cancer-associated bone disease revealed, as expected [316,
318], significant areas of tumor-induced osteolysis in PAIII-bearing tibia compared to
sham controls. However, strikingly, osteolysis was not evident in the PAIII+MSC cohort
(Fig. 16g). Consistent with this observation, there were significantly higher numbers of
TRAcP-positive mature multinucleated osteoclasts at the tumor-bone interface in the
PAIII cohort compared to the PAIII+MSC, MSC or sham cohorts (Figure 23 h).
Conversely, histomorphometry analysis demonstrated significantly higher levels of bone
volume in the PAIII+MSC group compared to the PAIII cohort, which likely reflects
increased MSC differentiation into osteoblasts (Figure 23 i).

Figure 22-1: MSCs initially suppress prostate cancer growth in the bone
microenvironment.
a. b. Prostate cancer growth (PAIII) overtime in the presence (1:1 ratio) or absence of MSCs (n=8/group).
An MSC-alone group was also included as a control (n=7). Representative images of bioluminescence for
each group at day 11 time point are shown. Graphs illustrate collected RLUs over time for each group
thru days 11 and 14. b. Analysis of RLU values at day 11.

76

Figure 23-2: MSCs initially suppress prostate cancer growth in the bone
microenvironment.
c. and 14 in the PAIII vs. PAIII+MSC group. d. e. Ex vivo analyses from study endpoint of proliferative
and apoptotic indices using phospho-histone H3 (p-H3; red arrows; c) and cleaved caspase 3 (CC3; red,
arrows, d), respectively. Pan-cytokeratin (green) was used to identify prostate cancer cells. f.
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Representative images of smooth muscle actin staining (α-SMA; red) in tissues derived from the
PAIII+MSC group. Pan-cytokeratin (pCK; green) was used to localize prostate cancer cells. Dashed box
in merge represents area of magnification. G. X-ray analysis of cancer-induced bone destruction.
Representative X-ray from PAIII group is shown with dashed box defining area of magnification. Arrows
indicate areas of cancer induced bone destruction. The area of bone destruction was calculated as a
percentage of total volume. H. The number of osteoclasts (TRAcP positive; red, multinucleated; arrows)
per μm of bone was calculated in non-sequential sections derived from the PAIII and PAIII+MSC groups.
i. Trabecular bone volume (BV) was measured via histomorphometry on non-sequential H&E multiple
sections derived from each group and calculated as a percentage of total volume. Representative gross
H&E images are illustrated from the PAIII and PAIII+MSC group. Asterisks denotes statistical significance
(*p≤0.05, **p≤0.01) whereas NS denotes not significant.

Chronic MSC exposure selects for apoptosis resistant prostate cancer:
In vitro, we observed that some sensitive PCa cells treated with MSC CM persisted
even after 24 hours of exposure to CM and were able to form colonies. To assess if
MSCs promote the selection of apoptosis resistant subpopulations, we exposed
parental PAIII PCa cells (F0) to MSC CM for 72 hours and allowed the surviving clones
to grow out (F1). These cells underwent a consecutive round of MSC CM selection to
yield a second MSC CM-educated population (F2). Cell growth analysis showed stepwise progressive enrichment of cancer cells resistant to growth inhibition by MSCs,
F0<F1<F2 (Figure 25 a). Further, in direct co-culture experiments, with MSCs and
cancer cells seeded at varying ratios, we observed an inhibitory effect on F0 parental
cells but a proliferative effect on F2 MSC-selected cell lines (Figure 25 b). Consistent
with this phenotype, immunofluorescence assays for cleaved caspase-3 demonstrated
that apoptotic indices of F2 exposed to MSC CM were significantly lower than that of F0
cells (Figure 25 c). This effect was not limited to the PAIII PCa cells as chronic exposure
to MSCs also selects for apoptosis resistant DU145 cells (Fig. 17d). We noted that both
the F2 PAIII and F2 DU145 were also significantly more resistant to etoposide (ETX)
induced apoptosis (Figure 25 c and e). To test if apoptosis resistance was solely due to
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MSC-derived factors or was more generalizable, we also examined the sensitivity of F0
and F2 cells to the chemotherapeutic drug docetaxel. Notably, MTT assays established
that the IC50 docetaxel for F2 generated PAIII cells was 24-fold higher than that of the
parental F0 cells (Fig. 17f).

We further examined differences in the RNA profiles

between the F0 and F2 PAIII and DU145 populations using RNA QuantSeq (Figure 28).
Pathway and network analyses revealed that apoptotic and survival pathways were
most impacted in the F2 prostate cancer cell populations underscoring that MSCs can
drive the selection for apoptosis-resistant sub-populations of prostate cancer.

Figure 24-1: MSCs select for apoptosis resistant prostate cancer cell populations.
a. Growth of parental PAIIIs (F0) and MSC PAIII cell lines selected after one (F1) or two rounds (F2) of
exposure to MSC conditioned media (50% concentration). Cell growth was calculated as a percentage of
controls grown in the absence of MSC CM. b. Direct co-culture of F0 and F2 PAIIIs with MSCs at varying
ratios (MSC:PAIII). Cell growth was calculated as a percentage of F0 and F2 PAIIIs seeded at equivalent
numbers in the absence of MSCs. c. Immunofluorescence (IF) analysis of cleaved cspase-3 positivity
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(green) in F0 and F2 PAIII cell lines treated for 6 hours with MSC CM. Graphs illustrate the number of
cleaved caspase-3 positive cells as a ratio of total cell number (nuclear DAPI-blue) per multiple fields of
view. Etoposide (ETX; 50μM) was used as a positive control.

Figure 25-2: MSCs select for apoptosis resistant prostate cancer cell populations.
d. e. MSC CM (50%) selection of apoptosis resistant DU-145 prostate cancer cells (F2) and the response
to etoposide (ETX; 50μM). Cell growth was calculated by MTT assay with absorbance (ABS) at 490nm
used as a correlate for cell number. F. IC50 curves of PAIII F0 and MSC selected F2 cells treated with
docetaxel for 48 hours at a concentration range of 0 to 6.25nM. Asterisks denotes statistical significance
(*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001) while NS denotes not significant.

Figure 26-1: RNA Quant profile of MSC educated PAIII and DU145 cell lines
a. b. Volcano plot showing log2 fold changes RNA profile between in the F2 PAIII (a) and DU145 (b) cells
compared to their respective F0 controls.
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Figure 27-2: RNA Quant profile of MSC educated PAIII and DU145 cell lines
a. b. Volcano plot showing log2 fold changes RNA profile between in the F2 PAIII (a) and DU145 (b) cells
compared to their respective F0 controls. c. d. Network (c) and pathway (d) analyses of the RNA profiles
in the F2 PAIII and DU145 compared to their respective F0 controls.
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Figure 28-3: RNA Quant profile of MSC educated PAIII and DU145 cell lines
c. d. Network (c) and pathway (d) analyses of the RNA profiles in the F2 PAIII and DU145 compared to
their respective F0 controls.

MSCs accelerate prostate cancer progression in bone:
To assess the effects of MSC selection on bone metastatic prostate cancer disease
progression, immunocompromised animals were intratibially injected with luciferaseexpressing F0 and F2 PAIII cell lines (2x104; n≥7) in the presence or absence of mouse
MSCs (2x104; n≥7). Sham injected contralateral limbs in each animal served as an
internal baseline control. Analysis of bioluminescence over time showed that that the F2
cell line, rather than being suppressed by MSCs, grew at significantly faster rates
compared to all other cohorts (Fig. 19a). Interestingly, F0 and F2 PAIII-derived tumors
grew at comparable rates, suggesting that MSCs drive the accelerated growth effects of
the F2 PAIII cell line in vivo. In accord with the phenotypes manifest in vivo, IHC
analysis of α-SMA demonstrated the persistence of the MSCs in the cancer-bone
microenvironment over the course of the studies (Fig. 19b). Ex vivo analyses of the
proliferative indices of F0 versus F2 PAIII cells agreed with the in vivo bioluminescence
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readouts, where there were significantly higher rates of proliferation in the F2 PAIII cells
when grown with MSC compared to all other groups (Fig. 19c). Further, analysis of
apoptotic indices showed significantly more apoptosis occurring in the F0 MSC treated
group (Fig. 19d). Although there was little impact of MSC on parental versus F2 PAIII
prostate cancer cells on associated bone disease, as measured by μCT and
histomorphometry analyses (Fig. 19e and f), revealed significantly higher numbers of
osteoclasts in the F2 PAIII-alone cohort (Fig. 19g). While this is indicative of higher
rates of bone remodeling, it did not manifest as increased cancer-induced bone
destruction.

Figure 29-1: MSC-selected prostate cancer cell growth is promoted rather than
suppressed by the presence of MSCs.
a. Parental (F0 PAIII) and MSC selected (F2 PAIII) growth over time in the presence (1:1 ratio) or
absence of MSCs (n≥8/group). Representative images of bioluminescence in each group are shown at
day 11 time point. Graphs illustrate collected RLUs over time for each group. b. Representative images of
smooth muscle actin staining (α-SMA; red) in tissues derived from the F0 and F2 groups in the presence
or absence of MSCs. Pan-cytokeratin (pCK; green) was used to localize prostate cancer cells. Dashed
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box in merge represents area of magnification. c. d. Ex vivo analyses from study endpoint of proliferative
and apoptotic indices using phospohistone H3 (pHH3; red arrows; b) and cleaved caspase 3 (CC3; red,
arrows, b) respectively. Pan-cytokeratin (green) was used to identify prostate cancer cells.

Figure 30-2: MSC-selected prostate cancer cell growth is promoted rather than
suppressed by the presence of MSCs.
c. d. Ex vivo analyses from study endpoint of proliferative and apoptotic indices using phospohistone H3
(pHH3; red arrows; b) and cleaved caspase 3 (CC3; red, arrows, b) respectively. Pan-cytokeratin (green)
was used to identify prostate cancer cells. e.μCT scan analysis of cancer-induced bone destruction.
Representative μCT images of the trabecular bone are shown for the F0 and F2 PAIII group. The
trabecular bone volume was calculated as a ratio to total volume analyzed (BV/TV). f. Trabecular bone
volume (BV) was measured via histomorphometry on non-sequential H&E multiple sections derived from
each group and calculated as a percentage of total volume. Representative gross H&E images are
illustrated from the F0 and F2 groups. g. The number of osteoclasts (TRAcP positive; red, multinucleated; arrows) per μm of bone was calculated in non-sequential sections derived from each group.
Asterisks denotes statistical significance (*p≤0.05, ****p≤0.0001) whereas NS denotes not significant.

Proteinase-K treatment and heat inactivation of the MSC CM revealed that a soluble
protein was necessary for the observed apoptotic effects in co-culture with prostate
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cancer cells (Figure 30 a). To identify potential apoptosis inducing factors cytokine
arrays were performed, which revealed that Fas ligand (FasL), galectin 1 (GAL1), and
interleukin-28 (IL-28) were specifically found in MSC-derived conditioned media (Figure
30 b). All 144 cytokines in the array were classified as either no expression, low
expression or high expression (Table 2). A IL-28 is known to trigger apoptosis [299,
320-322] but has not been explored in the context of bone metastatic prostate cancer.
Analysis of publicly available datasets revealed that IL-28, and its cognate receptors
IL28Rα and IL10Rβ were expressed in prostate carcinoma compared to prostate
glandular epithelium (Figure 35 a-c). We also demonstrated the presence of the IL28Rα in pan-cytokeratin positive prostate cancer cells in human samples of bone
metastatic prostate cancer (Figure 35). Next, we tested if PCa cells were sensitive to IL28 induced apoptosis. Both F0 and F2 PAIII prostate cancer cells expressed IL-28Rα
and IL-10Rβ, whereas MSCs expressed IL-28 (Figure 32 c). Notably, using recombinant
IL-28, F2 PAIII cells were significantly more resistant to IL-28-mediated cell death, with
an IC50 >35-fold higher than that observed in the parental F0 cell lines (F0 IC50 =
244pg/ml, F2 IC50 = 9,145pg/ml; Figure 32 d). Further, addition of IL-28 neutralizing
antibody to MSC CM, but not of isotype-matched IgG, ablated MSC-induced apoptosis
of parental F0 PAIII cells (Figure 32 e). Similarly, efficient shRNA-directed knockdown of
IL-28Rα expression in parental PAIII cells blocked MSC- and IL-28-induced apoptosis
without affecting the growth of these cells (Figure 32 f and g). In contrast, MSC CM or
recombinant IL-28 triggered rapid decreases in cell number in scrambled shRNA control
cells (Figure 32 g). Similar findings were observed following shRNA-directed knockdown
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of IL-28Rα in DU145 PCa cells (Figure 32 h, i), confirming the role of MSC-derived IL-28
in mediating the observed apoptotic effect.

Figure 31-1: MSC-derived IL-28 directs PCa apoptosis
MSC-derived IL-28 directs PCa apoptosis. a, PAIII growth (F0) in response to treatment with MSC CM,
heat-inactivated (HI) MSC CM, or proteinase-K (PK) treated MSC CM. b, Cytokine Array of MSC CM.
Black box indicates positive control (+ve), red box indicates IL-28. c, RT-PCR analysis of PAIII (F0 and
F2) of IL28Rα, IL-10Rβ and IL-28 expression. Molecular weights in base pairs are shown. d, Growth of
PAIII (F0) in MSC CM immune-depleted of IL-28 (MSC αIL-28). IgG was used as negative control (MSC
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IgG). Growth is expressed as a percentage of non-treated cells. e, Treatment of PAIII F0 and F2 cell lines
with the indicated concentrations of recombinant IL-28 (rIL-28) for 48 hr. f, Growth of IL-28Rα silenced
(sh-IL28R) and scrambled control (sh-SCR) compared to parental PAIII cell lines.

Figure 32-2: MSC-derived IL-28 directs PCa apoptosis
g, h, Control (sh-SCR) and IL-28Rα (sh-IL28R) PAIII and DU145 growth in MSC CM or rIL-28 as
measured by luminescence assay and relative light unit (RLU) measurement or MTT assay. Asterisks
denotes statistical significance (**p≤0.01, ****p≤0.0001) while NS denotes not significant.

Table 4: Expression of each of the cytokines on all three arrays after exposure to MSC
CM.
Expression of each of the cytokines on all 3 arrays after exposure to MSC CM. Score 0 = array showed
no expression 1=expression at high exposure only (low expression) 2=array showed expression at low
exposure (high expression)

Array #3

2

2

bFGF
CD26
(DPPIV)

Array #5
4-1BB
(TNFRSF9)
6Ckine
(CCL21)

1

ACE

1

2

Dtk

1

ALK-1

2

Score

Array #4
Cytokine

Score

Cytokine
Axl
BLC
(CXCL13)
CD30L
(TNFSF8)

1
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2
2

Table 4: (Continued)
CD30
(TNFRSF8)
CD40
(TNFRSF5)

3
1

CRG-2
CTACK
(CCL27)
CXCL16
Eotaxin-1
(CCL11)
Eoxaxin -2
(CCL24)
FasL
(TNFSF6)
Fractalkine
(CX2CL1)
GCSF
GM-CSF
IFN-gamma

1

IGFBP-3

2

IGFBP5
IGFBP6
IL-1 alpha
(IL-1F1)
IL-1beta
IL-2

2
2

IL-3
IL-3 beta
IL-4
IL-5

1
2
2
1

IL-6
IL-9

3
1

IL-10
IL-12
(p40/p70)
IL-12 p70

1

E-Selectin
1
Fc
gamma
RIIB
1

AR

2

CT-1
CD27
(TNFRSF7)
CD27 ligand
(TNFSF7)
CD36 (SRB3)
CD40 ligand
(TNFSF5)

0

Chordin
CTLA-4
(CD152)

1

3
2
1
1

1

Decorin
DKK-1
E-Cadherin
EGF
Endoglin
(CD105)

1

2

Flt-3 ligand
GITR
(TNFRSF18)
HGFR
ICAM-1
(CD54)

1

IGFBP-2

3

2

IGF-1

2

1
2
0
1

IGF-2
IL-15
IL-17RB
IL-17
I-TAC
(CXCL11)
Lungkine
(CXCL15)
MDC (CCL22)

2
1
1
1

2
1

Epigen
Epiregulin

1
2

MMP-2
MMP-3
OPN (SPP1)
OPG
(TNFRSF11B)
Pro-MMP-9
Rseistin
shh-N
TCK-1
(CXCL7)
TIMP-2
TRANCE
(TNFSF11)
TROY
(TNFRSF19)
TSLP

3
3
2

3
2
2

1
1
1
1

Galectin-1
Gas 1
Gas 6
GITR ligand
(TNFSF18)
Granzyme B
HAI-1
HGH

2
2

IL-1R4 (ST2)
IL-11

2
2

1

IL-17B

2

1
1

IL-17E (IL-25)
IL-17F

2
2

2
2

2
1
1

1
1

1
1
2
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1
0
1
1

2

1

1
1
1
2

Table 4: (Continued)
IL-13
Il-17A
KC (CXCL1)
Leptin R
Leptin

2
1
2
2
2

VEGFR1
VEGFR2
VEGFR3
VEGF-D

1
1
1
1

Figure 33-1: IL-28Rα expression in human prostate cancer
a-c. Public database analysis of IL-28 a, IL-28Rα

89

IL-1RA
(IL1F3)
IL-2 R alpha
IL-20
IL-21
IL-28A
IL-6R
JAM-A
(CD321)
MAdCAM-1
MFG-E8
Neprilysin
Pentraxin-3
(TSG-14)
Prolactin
RAGE
TAC1
(TNFRSF13B)
TREM-1
TWEAK
(TNFSF12)
TWEAK
R
(TNFRSF12)

2
2
1
2
2
2
2
1
2
2
2
2
1
1
2
1
2

Figure 34-2: IL-28Rα expression in human prostate cancer
a-c. Public database analysis of IL-28 a, IL-28Rα b, and IL10Rβ c, in human prostate gland (control) and
primary prostate cancer tissue.
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Figure 35-3: IL-28Rα expression in human prostate cancer
d. Representative images of IL-28Rα staining (red) in human samples of bone metastatic prostate (n=10;
three representative images are shown). Pan-cytokeratin (pCK; green) was used to localize prostate
cancer cells while DAPI (blue) was used as a nuclear stain. Dashed box in merge represents area of
magnification.

Development of MSC-derived resistance selects for IL-28-STAT3 signaling:
Despite clear differences in sensitivity to IL-28-induced apoptosis, levels of IL-28Rα
were similar in F0 versus F2 cell lines nor did we observe any differences in receptor
induction in response to MSC CM over time (
Figure 36). IL-28Rα induces phosphorylation of STATs via JAK/TYK kinase activation
[323]. In the context of cancer, STAT1 is considered a tumor suppressor while STAT3 is
often associated with tumor progression [324]. Consistent with previous publications
[325],

analysis

of

human

bone

metastatic
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specimens

(n=10)

demonstrated

phosphorylated STAT3 in pan cytokeratin positive prostate cancer cells (Figure 37). We
therefore assessed the activity of STAT1 and STAT3 in our PCa cell models by
monitoring their phosphorylation status. In independent experiments, we observed that
at steady state, both PAIII and DU145 F0 cell lines had significantly higher levels of
pSTAT1 (Tyr 701) compared to their respective F2 cell lines (Figure 38 a; 0 minute time
point). Conversely, baseline pSTAT3 (Tyr 705) levels were reduced in the PAIII F2
versus F0 cells but comparable levels were noted in the DU145 cell lines (Figure 38 a;
0-minute time point). Notably, treatment with MSC CM resulted in select differences in
pSTAT1 and pSTAT3 signaling in the F0 and F2 cell lines at 1, 5 and 10 minutes. Using
quantitative STAT activity assays, we observed that MSC conditioned media
significantly enhanced STAT1 activity in the PAIII and DU145 F0 cell lines compared to
F2 response (Figure 38 c and d). Conversely, we identified that MSC CM significantly
increased STAT3 activity in the PAIII F2 cell lines (Figure 38 c) but for DU145, MSC CM
significantly lowered STAT3 activity in the F0 cells while having no effect on the F2
population (Figure 38 d).

These data suggest that the MSC-selected apoptosis-

resistant prostate cancer cells exhibit STAT3 predominantly to STAT1 signaling.
Finally, in accord with its known pro-tumorigenic roles [326], siRNA-directed knockdown
of STAT3 (Figure 38 e and g), reduced the growth of all PCa cells with the addition of
MSC CM to the STAT3-silenced cells elicited no significant effect on cell viability (Figure
38 f and h).
STAT3 inhibition suppresses the growth of MSC-educated prostate cancer cells:
JAKs mediate IL-28Rα and IL-10β signal transduction [320], and several JAK inhibitors
have entered the clinical setting [327].
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Figure 36: IL-28Rα and IL-10Rβ expression in F0 and F2 PAIII and DU145 cell lines.
a. IL-28Rα and IL-10Rβ expression in F0 and F2 PAIII and DU145 cell lines. B. STAT3 phosphorylation in
PAIII parental (PAIII), scrambled control (sh-SCR) and IL-28Rα silenced (sh-IL28Rα) cell lines in
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response to treatment with recombinant IL-28 (rIL-28; 25ng/ml) for 15 minutes. Actin was used a loading
control. Molecular weights are shown in kDa. c-f. Realtime qPCR analysis of IL28Rα and IL10Rβ in F0
and F2 PAIII (c, d) and DU145 (e, f) cells lines in response to MSC CM at 1, 5, 10 and 60 minutes.
Asterisk denotes statistical significance (*p≤0.05).

Figure 37: pSTAT3 localization in human bone metastatic prostate cancer specimens.
Representative images of pSTAT3 staining (red) in human samples of bone metastatic prostate cancer
(n=10; five representative patients are shown). Pan-cytokeratin (pCK; green) was used to localize
prostate cancer cells while DAPI (blue) was used as a nuclear stain. Dashed box in merge represents
area of magnification. Arrows used to identify pSTAT3 staining in prostate cancer cells while arrow heads
identify positive staining in the supporting bone stromal cells.

Treatment with the JAK1/JAK2 inhibitor ruxolitinib reduced STAT3 phosphorylation and
impaired the growth of both F0 and F2 MSC-selected F2 PAIII and DU145 cells (

Figure 40 a and Figure 27 a). Of note, in this system, ruxolitinib and S3I-201 elicited no
significant effect on STAT1 activity (Figure 42 a).

94

Figure 38: Elevated STAT3 signaling in MSC-selected prostate cancer cell lines.
a. b. pSTAT1 and pSTAT3 levels at baseline and in response to MSC CM (50%) over a 10minute (min)
period in PAIII (a) and DU145 (b) parental (F0) and MSC selected (F2) cell lines. Molecular weights are
shown in kDa. Actin was used as a loading control. c. d. STAT1 and STAT3 activity in the PAIII (c) and
DU145 (d) was measured in response to MSC CM for 30 minutes. e. f. STAT3 was silenced (si-STAT3)
in PAIII (e) and DU145 (f) F0 parental and F2 MSC-selected cell lines and the resultant impact on STAT3
activity was measured. Blots show total STAT3. g. h. The effect of STAT3 silencing on PAIII (g) and
DU145 (h) cell growth in the presence or absence of MSC CM compared to control treated cells using
luminescence assay and relative light unit (RLU) measurement or MTT assay. Molecular weights are
shown in kDa. Asterisks denotes statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001)
while NS denotes not significant
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We next focused on specific inhibition of STAT3. Translational efforts in this area have
proven challenging, but the development of STAT3 inhibitors is important given high
levels of pSTAT3 in advanced cancers [324-326, 328]. In collaborative efforts, we
previously developed S3I-201, an inhibitor that prevents STAT3 dimerization, and
demonstrated its efficacy in treating breast cancer growth in vivo with no noted toxicities
[302]. Notably, treatment with S3I-201 selectively impaired the growth of the MSCselected F2 PAIII and DU145 cell lines with little effects on F0 parental cell lines (Figure
26 b). The specificity of S3I-201 was confirmed in STAT3-silenced F2 cell lines, where
treatment led to no further decrease in cell growth than that provoked by knockdown of
STAT3 alone (Figure 26 c). To test the sensitivity of the F2 generated prostate cancer
cell lines to STAT3 inhibition, we assessed the efficacy of the S3I-201 inhibitor in vivo.
Mice were intratibially injected with luciferase expressing F0 and F2 DU145 cell lines
and randomized after 7 days into vehicle control (n=10) or S3I-201 groups (n=10). Over
time we observed that S3I-201 significantly reduced the intraosseous growth of the F0
and F2 groups compared to their respective controls (Figure 26 d). Normalization to
controls at study endpoint further demonstrated that S3I-201 was more effective in
reducing the growth of the F2 DU145 compared to the F0 DU145 population (Figure 26
e). Ex vivo analyses of the injected tibia revealed that S3I-201 significantly inhibited the
proliferation of the F0 and F2 PCa cells (pHistone H3) while augmenting the apoptosis
index (cleaved caspase-3), particularly in the F2 group (Figure 26 f, g). Consistent with
reduced cancer growth, S3I-201 also protected against cancer associated bone disease
as measured by μCT, X-ray, histomorphometry and TRAcP staining (Figure 44). S3I-
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201 also effectively limited the growth of F2 PAIII PCa cell lines in vivo and significantly
suppressed proliferation (pHistone H3) (Figure 46). Despite decreased tumor growth,
we detected no differences in cancer-associated bone disease, but this might be due to
the rapid nature of the PAIII model (2 weeks) compared to the DU145 model (6 weeks).
Importantly, however, our findings establish that MSC-selected apoptosis-resistant F2
prostate cancer cells are highly sensitive to STAT3 inhibition in vivo.

Figure 39-1: STAT3 inhibition impairs the growth of MSC-selected prostate cancer in
vitro and in vivo.
a. b. Parental (F0) and MSC-selected (F2) cell lines treated with vehicle control (Control) or the JAK2
inhibitor ruxolitinib (RUX)/STAT3 inhibitor (S3I-201) for 24 hr. c. F0 and F2 DU145 control (scr-siRNA) or
STAT3 silenced (si-STAT3) cells treated with vehicle or S3I-201 for 24 hr. d. F0 and F2 DU145 growth
over time in the presence or absence of STAT3 inhibitor, S3I-201 (n=10/group). Representative images of
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bioluminescence in each group are shown at day 35 time point. Arrow and dashed line represent time of
treatment initiation. Graphs illustrate collected RLUs over time for each group.

Figure 40-2: STAT3 inhibition impairs the growth of MSC-selected prostate cancer in
vitro and in vivo.
d. F0 and F2 DU145 growth over time in the presence or absence of STAT3 inhibitor, S3I-201
(n=10/group). Representative images of bioluminescence in each group are shown at day 35 time point.
Arrow and dashed line represent time of treatment initiation. Graphs illustrate collected RLUs over time
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for each group. e. S3I-201 effect on F0 and F2 DU145 at day 42 normalized to respective controls. f. g.
Ex vivo analyses from study endpoint of proliferative and apoptotic indices using phospohistone H3
(pHH3; red arrows; f) and cleaved caspase 3 (CC3; red, arrows, g) respectively. Pan-cytokeratin (green)
was used to identify prostate cancer cells. Asterisks denotes statistical significance (*p≤0.05, **p≤0.01,
***p≤0.001, ****p≤0.0001) whereas NS denotes not significant.

Figure 41-1: STAT3 phosphorylation status in response to ruxolitinib and S3I-201.
a-d. STAT3 and STAT1 phosphorylation and activity was assessed in response to ruxolitinib (Rux;
100nM) and S3I-201 (100 μM) treatment overnight in F0 and F2 PAIII (a, b) and DU145 (c, d) cell lines.
Subsequently, MSC CM was added to each condition for 30 minutes prior to lysis and analysis. Actin
was used as a positive loading control. Molecular weights are shown in kDa. Asterisks denotes statistical
significance (*p≤0.05, **p≤0.01, ***p≤0.001) whereas NS denotes not significant.
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Figure 42-2: STAT3 phosphorylation status in response to ruxolitinib and S3I-201.
a-d. STAT3 and STAT1 phosphorylation and activity was assessed in response to ruxolitinib (Rux;
100nM) and S3I-201 (100 μM) treatment overnight in F0 and F2 PAIII (a, b) and DU145 (c, d) cell lines.
Subsequently, MSC CM was added to each condition for 30 minutes prior to lysis and analysis. Actin
was used as a positive loading control. Molecular weights are shown in kDa. Asterisks denotes statistical
significance (*p≤0.05, **p≤0.01, ***p≤0.001) whereas NS denotes not significant.
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Figure 43-1: STAT3 impacts prostate cancer associated bone disease in the F0 and F2
DU145 model.
a. μCT scan analysis of cancer-induced bone destruction. Representative μCT images of the trabecular
bone are shown for the vehicle alone and S3I-201 F0 and x. The trabecular bone volume was calculated
as a ratio to total volume analyzed (BV/TV). b. Faxitron X-ray analysis of cancer-induced osteolytic
lesions. Representative images of the X-rays are shown for each group. The size of the tumor volume as
measured by the area of the lytic lesion (TuV) was calculated as a ratio to total volume analyzed
(TuV/TV).
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Figure 44-2: STAT3 impacts prostate cancer associated bone disease in the F0 and F2
DU145 model.
c. Trabecular bone volume (BV) was measured via histomorphometry on non-sequential hematoxylin and
eosin (H&E) multiple sections derived from each group and calculated as a percentage of total volume.
Representative gross H&E images are shown for the vehicle and S3I-201 F0 and F2 groups. d. The
number of osteoclasts (TRAcP positive; red, multi-nucleated; arrows) per μm of bone was calculated in
non-sequential sections derived from each group. Representative gross TRAcP images are shown for the
vehicle and S3I-201 F0 and F2 groups Asterisks denotes statistical significance (*p≤0.05, **p≤0.01,
***p≤0.001, ****p≤0.0001) whereas NS denotes not significant.
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Figure 45-1: STAT3 inhibition impairs the growth of MSC-selected prostate cancer in
vitro and in vivo.
a. F0 and F2 PAIII growth over time in the presence or absence of STAT3 inhibitor, S3I-201 (n≥8/group).
Representative images of bioluminescence in each group are shown at day 11 time point. Arrow and
dashed line represent time of treatment initiation. Graphs illustrate collected RLUs over time for each
group. b. S3I-201 effect on F0 and F2 PAIII at day 11 normalized to respective controls. c. d. Ex vivo
analyses from study endpoint of proliferative and apoptotic indices using phospohistone H3 (pHH3; red
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arrows; b) and cleaved caspase 3 (CC3; red, arrows, c) respectively. Pan-cytokeratin (green) was used to
identify prostate cancer cells.

Figure 46-2: STAT3 inhibition impairs the growth of MSC-selected prostate cancer in
vitro and in vivo.
e. μCT scan analysis of cancer-induced bone destruction. Representative μCT images of the trabecular
bone are shown for the vehicle alone and S3I-201 F0 groups. The trabecular bone volume was calculated
as a ratio to total volume analyzed (BV/TV). f. Trabecular bone volume (BV) was measured via
histomorphometry on non-sequential hematoxylin and eosin (H&E) multiple sections derived from each
group and calculated as a percentage of total volume. Representative gross H&E images are shown for
the vehicle and S3I-201 F0 groups. g. The number of osteoclasts (TRAcP positive; red, multi-nucleated;
arrows) per μm of bone was calculated in non-sequential sections derived from each group.
Representative gross TRAcP images are shown for the vehicle and S3I-201 F0 groups Asterisks denotes
statistical significance (*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001) whereas NS denotes not significant.
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Discussion:
Bone metastatic prostate cancer remains incurable and affects the majority of men
diagnosed with recurrent castrate resistant disease. These metastatic lesions are
associated with extensive bone remodeling, which generates factors that promote the
growth, survival and persistence of prostate cancer cells in the face of applied systemic
ADT and chemotherapies [229, 290, 329].

Understanding how osteoblasts and

osteoclasts mediate these effects has led to the development of therapies that target
the microenvironment such as the RANKL-binding monoclonal antibody denosumab
and nitrogen-containing bisphosphonates that block osteoclast formation and activity
[290].
While effective in preventing skeletal pathologies such as fracture, these
therapies are, unfortunately, largely palliative.

The heavy infiltrates of osteoblast

progenitor MSCs in bone metastatic prostate cancer we observed is not surprising
considering the bony nature of these lesions, [313, 330] and that prostate cancers are
known to drive MSCs into an osteoblastic phenotype [289, 312, 313, 331]. However, the
dynamic effects of MSCs in promoting apoptosis and hence the selection for therapy
resistance disease via MSC-derived IL-28 was unexpected, where MSC-derived IL-28induced apoptosis drives the selection for broadly resistant subpopulations that are
growth stimulated rather than repressed by MSCs. Further, the switch from apoptosis
sensitivity to resistance was accompanied by a shift in STAT1 to STAT3 signaling that
we have shown represents a vulnerability. Our in vivo studies demonstrated that STAT3
inhibition with S3I-201, was effective in significantly reducing the growth of MSCselected prostate cancer. Our working hypothesis is that upon entry into the bone

105

marrow, metastatic prostate cancer cells interact with resident MSCs, resulting in the
elimination of a majority of the cancer cells being eliminated. Over time however, MSCs
eventually select for prostate cancer cells that are refractory to IL-28-induced apoptosis
and that exhibit increased STAT3 signaling.

Interestingly, we found that the MSC-

selected prostate cancer cells are also cross-resistant to chemotherapies such as
etoposide and docetaxel suggesting that STAT3 inhibition could be a viable route to
resensitizing bone metastatic prostate cancer that is refractory to chemotherapy.
The tumor-promoting properties of MSCs revealed herein are largely in accord
with studies establishing that MSCs contribute to, and in some cases are necessary for,
tumor progression. For example, in breast cancer, intratumoral MSCs express
chemokine ligand 5 (CCL5) that promotes invasion and metastasis [255], and coinoculation with MSCs promotes progression and metastasis of both osteosarcoma and
ovarian cancer [256, 332]. Mechanisms ascribed to these effects include angiogenesis
and protection from hypoxia via the secretion of vascular endothelial growth factor
(VEGF), immune suppression/modulation, the suppression of apoptosis, and the
induction of the epithelial to mesenchymal transition (EMT) program [275, 276].
Consistent with the positive effect of MSCs on cancer cell growth, we have shown here
that bone-marrow derived MSCs enhance the proliferation of a subset of metastatic
prostate cancer cell lines such as C4-2B, which of notably is derived from in vivo LnCAP
bone metastases and exhibits endogenously elevated levels of STAT3 activity [333].
Conversely, MSCs can have tumor suppressive effects in hepatoma and glioma where
they induce cell-cycle arrest and apoptosis [334]. MSC-derived interferons (IFNs) have
been shown to trigger apoptosis in MCF-7 breast cancer cells via activation of STAT1
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[335]. Notably, a similar mechanism appears manifest in prostate cancer cells that are
vulnerable to MSC-derived IL-28 induced apoptosis via STAT1 activation.
As documented here, IL-28 joins a cast of other cytokines that activate STAT3,
including IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-31 [336,
337]. STAT3 has clear roles in driving cancer progression and therapy resistance [324,
325, 338-340] but rather little has been described regarding the tumorigenic roles of IL28. In a mouse model of B16 melanoma progression, IL-28 reduces tumorigenicity but
how this occurs is not clear and could reflect effects on immune surveillance [341]. This
remains an important area for future investigation in bone metastatic prostate cancer,
where syngeneic cell lines in immunocompetent animals (TRAMP-C3, Myc-CAP, RM1)
will allow for the study of MSCs and IL-28 on infiltrating immune cells.
In addition to IL-28, our cytokine array analysis also revealed the presence of
additional apoptotic factors in the MSC CM, such as FasL. Indeed, release of FasL via
matrix metalloproteinase-7 (MMP-7) has been shown to be responsible for prostate
epithelial cell apoptosis during involution of the organ subsequent to castration [342].
This phenomenon has also been demonstrated in the mammary gland where
expression of a MMP-7 transgene in mammary epithelium augments apoptosis and
involution at weaning but eventually provokes the development of hyperplasia in
multiparous mice [343]. Further, chronic exposure of breast cancer cells to soluble FasL
selects for apoptosis resistant subpopulations [344]. However, in our models, PAIII are
sensitive to FasL-induced apoptosis (Figure 47), immunodepletion of IL-28 completely
abrogates the apoptotic effects of MSC CM (Figure 32 e).
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MSC-selected apoptosis-resistant prostate cancer cells exhibit elevated pSTAT3,
consistent with the hyperactivation of STAT3 signaling observed in many human
cancers where that correlates with poor prognosis and resistance to chemotherapy and
radiation therapy [339, 345]. In bone metastatic prostate cancer, IHC analyses have
revealed that the majority of cases studied are positive for STAT3, and kinome profiling
have shown elevated activity of JAK2, which phosphorylates STAT3 at Tyr705 resulting
in head to tail dimerization, translocation to the nucleus and binding to the promoters of
target survival genes such as BCL-xL and survivin [346]. Here, we have shown
preferential STAT3 activity in MSC/IL-28-resistant prostate cancer that confers
resistance to chemotherapies used to treat bone metastatic prostate cancer. Since
there is no change in the level of IL28Rα or IL10Rβ, it is not clear at this juncture what
causes the termination of STAT1 phosphorylation in the MSC-educated prostate cancer
cells. STAT inactivation can be controlled by a number of mechanisms that might be
altered between the F0 and F2 populations including protein tyrosine phosphatases that
depending

on

kinetics

and

cellular

compartmentalization

may

preferentially

dephosphorylate specific STATs [347-349]. Suppressors of cytokine signaling (SOCS)
and protein inhibitors of activated STATs (PIAS) can also act as inhibitors of STATs or
direct them for protein degradation [347]. For example, STAT-interacting LIM protein
(SLIM) acts as a ubiquitin E3 ligase and can direct STATs, in particular, STAT1, for
proteasomal degradation [350]. Further, STAT3 itself can bind to STAT1 and prevent
the transcription of STAT1 target gene suggesting that STAT3 activity in the F2 cells
could further limit STAT1 activity [351]. RNA QuantSeq analysis comparing the MSC
educated F2 cell lines to their parental counterparts also demonstrated that genes such
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as SPRY2 (a negative regulator of interferon signaling and IFN inducible genes) were
significantly downregulated in MSC educated cells. Further, bioinformatic analyses of
the most downregulated pathways and networks in the MSC educated PAIII and DU145
F2 populations are; apoptosis regulated by mitochondrial proteins and apoptotic
mitochondria respectively (Figure 28).

Interestingly, STAT3 has been shown to

accumulate in the mitochondria [352], prevent mitochondrial mediated apoptosis and is
linked to enhanced survival and drug resistance [353, 354]. We should also note that
deletion of STAT3 and PTEN in genetically engineered mouse models demonstrated a
protective effect on prostate cancer progression and soft tissue metastasis (liver and
lungs) [340] . Further, STAT3 expression was detected in only ~40% of metastases but
the location of the metastases was not obvious. The tumor microenvironmental context
of the metastases can have profound effects on cancer cell behavior. Given that other
reports have reported high STAT3 positivity in bone metastatic prostate cancer [325]
and that the majority of prostate cancer in humans metastasizes to the skeleton, we
believe that STAT3 may be an important regulator of prostate cancer progression,
specifically in bone. Importantly, STAT3 is also revealed here to be a targetable
vulnerability that disables the growth of bone metastatic PCa, suggesting that STAT3
inhibitors such S3I-201 [302], which appears well-tolerated in pre-clinical studies, and
have potential in the prostate cancer clinic. Alternatively, FDA-approved JAK2 inhibitors
such as ruxolitinib could be considered for the treatment of metastatic CRPC patients,
yet to date, ruxolitinib has produced only very modest effects in phase II clinical trials
(NCT00638378), suggesting more specific targeting of JAK2 or better delivery methods
are required to realize the therapeutic potential of JAK2 inhibition.
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In conclusion, we have shown that bone marrow-derived MSCs drive the
emergence of apoptosis resistant subpopulations of prostate cancer cells via the
chronic exposure to MSC-derived IL-28 and that this is associated with increases in
STAT3 activity that are necessary for the maintenance of bone metastatic PCa. Our
findings also indicate that the application of STAT3 inhibitors may resensitize prostate
cancer cells to chemotherapy and that, given the role of STAT3 activity in the
progression of a wide range of cancers, the mechanism described herein may have
broad applicability to other skeletal malignancies and/or metastases.

Materials and Methods:
Cell lines, culture and animals:
LNCaP (Cat # CRL-1740), DU145 (HTB-81), MC3T3 (CRL-2594), RWPE-1 (CRL11609), V-CAP (CRL-2876), 22RV1 (CRL-2505) MyC-CaP (CRL-3255) cell lines were
purchased from the ATCC. PC3-2M cells were purchased from Perkin Elmer, PrEC
prostate epithelial cells (CC-2555) and human MSCs (PT-2501) were purchased from
Lonza while PAIII cells [27] and C4-2B [67] were kindly donated. All cell lines were
periodically mycoplasma tested (CUL001B, R&D Systems) and short tandem repeat
(STR) verified at the Moffitt Clinical Translational Research Core. Cell lines were
passaged in recommended culture medium supplemented with 10% fetal calf serum
(FCS). Isolation and culture methods for mesenchymal stem cells (MSCs) were adapted
from previously published protocols [355].
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Figure 47: MSC-derived FasL promotes PCa apoptosis.
a. Cytokine Array of MSC CM. Positive control and levels of FasL and IL-28 are illustrated. Cytokine Array
of MSC CM. Black box indicates positive control, red box indicates IL-28. b. PAIII response to increasing
concentrations of FasL for 48 hours. Anti-HA alone was used as a control. c. d. F0 and F2 PAIII and
DU145 cell lines treated in the presence or absence of recombinant FasL (10ng/mL) for 48 hours. e.
Immunofluorescence (IF) analysis of cleaved caspase-3 positivity (green) in F0 (d) and F2 (d) PAIII cell
lines treated for 6 hours with rFasL. Graphs illustrate the number of cleaved caspase-3 positive cells as a
ratio of total cell number (nuclear DAPI-blue) per multiple fields of view. Etoposide (ETX; 50μM) was used
as a positive control. Asterisks denotes statistical significance (**p≤0.01, ****p≤0.0001) whereas NS
denotes not significant.

Briefly, hind limbs were collected from tumor-naïve 4–6-week-old male C57/BL6
Rag2−/− mice in sterile PBS. Following removal of muscle tissue, epiphyses were
removed, and bone marrow flushed three times with sterile PBS to deplete the
hematopoietic cells. Flushed bones were then cut into 1–3 mm chips, digested with
1 mg/mL collagenase II (Invitrogen) in α-MEM with 15% FBS, and shaken at 150 RPM
for 1 hour at 37 °C. Digested bone fragments were grown in 6-well tissue culture plates
in α-MEM with 15% FCS. Medium was changed every 3 days. For direct co-culture
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experiments, cancer cells expressing luciferase were cultured with murine MSCs at
multiple ratios seeded for a total density of 2×104 in 48-well plates. Co-cultures were
incubated for 48 hours, and PAIII growth was measured by bioluminescence using the
Promega Luciferase Assay System (E1500) per manufacturer's instructions. For
analyses assessing the growth of cancer cell lines in response to MSC CM, MTT
assays were used. Prostate cancer cell lines were plated in 96-well plates at a density
of 1×104 cells/well and treated with MSC conditioned media. Cell viability was measured
at 48 hours by the MTT assay per manufacturer's protocols (CellTiter 96, #G3582,
Pierce) by measuring absorbance at 490nm after 4 hours of incubation at 37°C.
MSC characterization by FACS analysis:
The Mouse Mesenchymal Stem Cell Multi-Color Flow Kit (R&D Cat # FMC003) was
used according to manufacturer’s protocol. Isolated MSCs were assessed by flow
cytometry for CD29 and SCA-1 positivity and CD45 negativity. For FACs analysis 1X106
MSCs were suspended in flow cytometry staining buffer. For each marker 90μl of the
cell suspension were transferred to 5ml flow tubes and incubated for 30 minutes with
each antibody or isotype control. Cells were then washed twice in 2 ml of flow cytometry
staining buffer and resuspended in 200μl of the same buffer for analysis.
Differentiation assays:
Osteogenic differentiation and staining: MSCs grown to confluency before treatment
with 20X murine osteogenic supplement (R&D Cat# CCM009) added to normal growth
medium and changed every 2-3 days for 21 days. Negative controls were grown in
normal growth medium. Cells were then stained with Alizarin Red (Fisher scientific Cat
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# 130-22-3). Cells were washed gently 3 times in PBS and fixed for 15 minutes using
10% buffered formalin. Fixed cells were washed 2 times with ddH20 and then stained in
the dark for 45 minutes in 2% alizarin red solution. (Note pH is critical for 2% Alizarin
Red solution pH 4.2-4.3 adjusted using 10% ammonium hydroxide). Cells were washed
gently 4 times with ddH20 and air dried before images were acquired. For adipogenic
differentiation and staining: MSCs were grown to confluency and then treated with 100X
Adipogenic supplement (R&D Cat# CCM011) in normal growth medium or negative
control in normal growth medium changed every 2-3 days for 21 days. Cells were
stained with Oil Red O. (Sigma Cat# 01391). Cells were washed with PBS and then
stained using 1-part Oil Red O 1-part water for 15 minutes. Cells washed 3 times with
ddH2O and imaged for red oil droplets. For chondrogenic differentiation and staining:
MSCs were trypsinized and counted 1.5X105 cells were spun down at 200g for 5
minutes in 6 15 ml conical tubes. The media was then replaced with media containing
100X chondrogenic supplement (R&D Cat# CCM006) or just base media in triplicate.
The caps of the tubes were loosened and incubated at 37oC. After 2 days the cells
formed small spheres and the media was replaced every 2-3 days for 28 days. The
pellets were then washed in PBS and embedded in paraffin for histology. Consecutive
slides were H&E stained and the second slide stained with Alcian Blue (Sigma Cat #
B8438). For Alcian Blue staining slides were dewaxed in xylenes rehydrated to water
and stained for 30 minutes in Alcian Blue solution. Slides were then washed in running
tap water for 2 minutes followed by a rinse in H2O. Slides were then dehydrated to
100% ethanol and cleared in xylenes before mounting cover slips with permount and
imaging.
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Migration assay:
Cells were serum starved for 2 hours before trypsinizing and seeding (2x105 cells) into
upper chambers of 24-well Transwell membrane assay system (Corning). Lower
chambers were prepared either 650µl of either serum free, 1% serum or MSC CM. All
conditions were performed in triplicate and incubated for 5 hours at 37ᵒC. After
incubation, upper chambers were rinsed in diH2O water followed by 1X PBS and fixation
in methanol at -20ᵒC for 20 minutes. The chambers were then rinsed in water followed
by 1X PBS, and non-migrated cells removed by gentle scrubbing with cotton tip
applicators. After rinsing in diH2O, membranes were stained with hematoxylin and
dehydrated with 100% ethanol. The membranes were air dried dry and excised using a
scalpel before mounting on slides with Permount (Fisher Cat # SP15-100). Three fields
of view from each membrane were acquired using brightfield microscopy and the
number of migrated cells per field counted.
Intratibial tumor studies:
Mice were purchased from Jackson Laboratory. All animal experiments were performed
with IACUC approval (R1762, CCL) and in accordance with the guidelines set forth in
the Guidelines for the Care and Use of Laboratory Animals published by the National
Institutes of Health. six-week old male Rag2-/- mice were intratibially injected with
luciferase-expressing PAIII or murine MSCs (2×104 cells 20μl of sterile saline), or PAIIIs
and murine MSCs 1:1 for a total of (4X104 cells 20µl of sterile saline). Six-week old
NSG mice were intratibially injected with luciferase-expressing DU145 cells (5X105 in
20ul of sterile saline). Contralateral limbs were injected with saline to control for injury
induced changes. For S3I-201 in vivo studies, tumors were allowed to establish for 3
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days before randomizing groups for treatment with S3I-201 (5mg/kg) or sterile PBS
administered by intraperitoneal injections in 200-µl volumes every other day.
Bioluminescence for all studies was measured twice weekly as a correlate of tumor
growth (IVIS™ Perkin Elmer). Mice that showed tumor growth outside of the bone
compartment were excluded from all analyses.
Cell line conditioned media collection and treatment:
MSCs were cultured in T-75 cell culture flasks until 80-90% confluent. Each flask was
rinsed three times with sterile 1X PBS before adding 5 mL of serum free medium. After
incubating for 24 hours, conditioned media (CM) was centrifuged at 4,000g for 5 min,
transferred to a new tube, and stored at 4ᵒC. Fresh CM was collected weekly and
stored at 4ᵒC. To test if the MSC-derived factor responsible for prostate cancer
apoptosis was a soluble protein, MSC CM and matched control serum free aMEM were
either heat inactivated at 95ᵒC for 30 minutes or treated with 100µg/ml proteinase K
followed by heat inactivation 95ᵒC for 30 minutes. PAIII cells were seeded at 3x104 cells
per well and treated with each respective media type for 24 hr. Cell growth was
analyzed by luminescence assay (Promega Luciferase Assay System, Cat # E1500).
For IL-28 neutralization studies; PAIII cells were seeded in white wall, solid bottom 96well plates (5x104 cells/well) and incubated for 24 hours before treatment with either
MSC CM or serum free media control containing either 10µg/ml of neutralizing antibody
(R&D, AF1789) or normal goat IGG (R&D, AB108C). Cells were incubated for 48 hr,
and growth was analyzed using the Promega Luciferase Assay System, Cat# E1500
per the manufacturer's protocols.
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For docetaxel, recombinant IL-28, JAK2 inhibition (ruxolitinib) and STAT3 inhibition
(S3I-201) parental (F0) or MSC-selected prostate cancer cells (F2) cells were seeded
(5X103) in 96-well plates and treated as follows. Docetaxel; 0, 0.0625, 0.125, 0.625,
1.25, 2.5, and 6.25 nM for 48 hours. Recombinant IL-28 (R&D mIL-28B, Catalog #1789ML); 0, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128ng/ml. Ruxolitinb; 0, 0.0001, 0.001, 0.01, 0.1,
1, and 10 μM. S3I-201 0, 0.1, 0.5, 1, 5, 10, 25, 50, 100, and 150μM. Cell growth was
assayed via luminescence or MTT assay.
Ex vivo bone analysis:
Tibias were collected and fixed in 10% formalin for 24-48 hours and then transferred to
50% ethanol. Radiographic images (Faxitron, X-ray Corp) were obtained using energy
of 35kVp and an exposure time of 8 milliseconds. The spatial resolution is 10 lp/mm
(48μm). The tumor volume (TuV) was calculated as a function of the total tissue volume
(TV) of the tibial medullary canal using ImageJ software. For μCT analysis, the proximal
tibia metaphyses were scanned (μCT-40; Scanco Medical). An evaluation of trabecular
bone structural parameters was performed in a region that consisted of 1mm starting at
500μm from the growth plate. A three-dimensional cubical voxel model of bone was
built, and calculations were made for relative bone volume per total volume and
trabecular number. After X-ray and µCT analysis, tibias were decalcified (14% EDTA,
pH 7.4, 3 weeks), processed, and paraffin embedded.
Immunofluorescence:
For paraffin embedded tissues, slides were dewaxed and rehydrated to water. Antigen
retrieval was performed by heat using a pressure cooker for 5 minutes in1X Tris EDTA
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pH 8.0. Proteinase K antigen retrieval was used for αSMA staining (7.5 minutes at
room temperature 5mL 2M Tris pH 7.5, 5 mL 0.2M EDTA, 190 mL ddH2O and 400 µL of
10mg/mL proteinase K). Slides were blocked in 10% goat serum in 1X TBS for 1-hour
room temperature. Primary antibodies (Pan Cytokeratin, Sigma-Aldrich Cat # C2562.
1:200 dilution; Phospho-Histone H3, Cell Signaling Cat #9701L, 1:200 dilution; Cleaved
Caspase 3, Cell Signaling Cat #9661S, 1:200 dilution; Alpha Smooth Muscle Actin
(1A4), Cell Signaling Cat # 48938, 1:200 dilution IL-28Rα, Bioss, Cat # ABIN1387718)
Cell Signaling Cat#9145 pSTAT3 Tyr705 (D3A7) 1:100 dilution, abcam Cat #ab92574
CD90/Thy1 [EPR3132] 1:100 and R&D Cat# MAB2636 Mouse/Rat Nestin 1:50 were
diluted in 10% normal goat serum (Vector Laboratories Cat # S-1000) and incubated
overnight at 4ᵒC in a humidified chamber. After 3 washes in 1X TBST followed by 1
wash in 1X TBS, secondary antibodies (Alexa FluorTM Goat Anti Rabbit 568, (Thermo
Fisher Scientific #A-11011); Alexa Fluor Goat Anti Mouse 488, (Thermo Fisher Scientific
#A32723) were incubated at a 1:1,000 dilution in 10% normal goat serum for 1 hour at
room temperature. Slides were washed three times in 1X TBS and mounted using
Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories, # H-1200).
Slides stored in the dark until image acquisition. At least 3 representative images of
tumor sections were acquired and analyzed with Image J.
For in vitro immunofluorescent analyses, PAIII cells were seeded into 8-well chamber
slides (LAB-TEK Cat #154534) at 2x104 cells per well and cultured overnight before
treatment with either 50% MSC CM or DMEM 5% FBS or 100nM etoposide for 5 hours
Cells were then rinsed with PBS and fixed in 4% PFA at room temperature for 20
minutes. Fixed cells were then blocked for 30 minutes at room temperature in antibody
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diluting buffer (2% BSA, 0.1% Triton X-100 in PBS). Primary antibodies (Cleaved
Caspase 3, Cell Signaling Technology, #9661S), 1:400 dilution in antibody diluting
buffer; Rabbit IgG Isotype Control, Thermo Scientific #31235) were incubated at room
temperature for 30 minutes. Cells were then washed 3x in PBS and incubated with
secondary antibody (Alexa FluorTM Goat Anti-Rabbit 488, Invitrogen #A-11034, 1:1,000
dilution in antibody diluting buffer) for 30 minutes at room temp in the dark. After
washing 3x in PBS, culture chambers were removed and the slides mounted with
Vectashield Antifade Mounting Medium with DAPI(Vector Laboratories, # H-1200).
Mounted slides were stored in the dark at 4ᵒC until microscopic analysis. Three
representative images were acquired at 40X magnification and the ratio of cleaved
caspase positive to negative cells calculated with ImageJ.
H&E and TRAP staining:
Formalin-fixed paraffin-embedded tissue sections cut5 μm thick were mounted on
microscope slides and stained with hematoxylin and eosin for histological analyses. For
TRAcP staining , slides were incubated in buffer (112 mM anhydrous sodium acetate,
49 mM dibasic dehydrate sodium tartrate, 0.28% glacial acetic acid) containing 1%
naphthol-phosphate substrate (2% napthol AS-BI phosphate in 2-ethoxyethanol) for
1 hour at 37 °C. Slides were then transferred to buffer containing 250 μl of 5%
pararosaniline dye in 2 N HCl and 250 μl of 4% sodium nitrite at 37°C and monitored for
development of red stained osteoclasts. Slides were rinsed in H2O, counterstained with
hematoxylin, and aqueously mounted. The number of bone-lining, multi-nucleated (>3
nuclei per cell), TRAcP positive osteoclasts was quantified from multiple sections.
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Immunoblotting:
Cells were lysed with RIPA (150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 20 mM Tris, pH 8). Protein concentration was determined by
BCA (Pierce, Waltham, MA, USA; #23225). Blots were blocked in 5% BSA for 1 hour
followed by primary antibody. All primary antibodies were purchased from Cell Signaling
Technology (Cleaved Caspase 3 #9661S, pSTAT1 Tyr701 #7649S, pSTAT1 Ser727
#9177, pSTAT3 Tyr705 (D3A7) #9145, STAT3 (D3Z26) #12640S, STAT1 #9172S
pJAK2 Y1007/1008 # 3776S), Santa Cruz (IL-10Rβ, Cat# sc271969) or Abcam (IL28Rα, Cat# ab83865). Primary antibodies were diluted 1:1,000 in blocking solution
+0.1% Tween-20, and were incubated overnight at 4°C. Beta Actin (Santa Cruz sc-1615
or Cell Signaling #3700) was used as a loading control. Blots were washed, then
incubated with HRP-conjugated anti-species secondary (Cell Signaling Technology,
Rabbit #7074/Mouse #7076, 1:1,000) and developed by enhanced chemiluminescence
followed by exposure to light-sensitive film or imaging by LI-COR Odyssey Fc.
Quantification performed with Image Studio software (LI-COR). MSC CM was analyzed
using Ray Biotech Mouse Cytokine Array C-2000 (AAM-CYT-2000) per manufacturer
protocols.
PCR gene expression:
RNA was extracted with TRIzol (Invitrogen #15596) from F0 and F2 PaIII and F0 and F2
DU145 after treatment with MSC CM for 0,1,5,10 and 60 minutes.

Reverse

transcription was performed using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems #4368813). PCR reactions were set up using HotStarTaq Master
Mix (Qiagen, #203445). PCR cycle conditions were 95ᵒC for 15 minutes, followed by 35
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cycles (95ᵒC for 30 sec, 57ᵒC for IL-28Rα and IL10Rβ or 55ᵒC for IL-28 and 18S; 30 se,
72ᵒC for 45 seconds. Primers for targets were as follows; Mouse IL-28 Forward 5′GTTCAAGTCTCTGTCCCCAAA
GTGGAACTGCACCTCATGT

-3′,

Mouse

-3′,

Rat

IL-28
IL-28Rα

Reverse

5′-

Forward

5′-

CCTGTTCCTGATGCAAAGCG-3′,

Rat

IL-28Rα

Reverse

5′-

AAGTAGGTCACATTCGGGGG-3′,

Rat

IL-10Rβ

Forward

5′-

GAACGGGAGAGTGGAGCAAA

-3′,

Rat

IL-10Rβ

Reverse

5′-

ATGCTGAAGCAGCCCAGTAG-3′, 18S Forward 5′-GTAACCCGTTGAACCCCATT-3′,
18S Reverse 5′-CCATCCAATCGGTAGTAGCG-3′.
shRNA and siRNA of IL-28Rα and STAT3:

Lentivirus expressing human or rat IL-28Rα shRNA (Origene, human;
HT144125A-D, Rat; HT144126A-D, scrambled control; TR30033) were
generated using standard procedures. PAIII and DU145 cells were seeded
into 6-well plates (1x106/well) and transduced with retrovirus in 4μg/ml
polybrene. After 24 hours the media was replaced with 2mls of 10% serum
containing DMEM without antibiotics for 48 hours to allow for recovery. Stable
clones were selected via treatment with media containing blasticidin (8µg/ml).
Prior to analysis, IL-28Rα levels were analyzed via immunoblot as described.
For STAT3 siRNA, 1x106 cells from each cell line were seeded into individual
6-well plates and incubated overnight. Cells were transfected using
lipofectomine RNAiMAX (Thermo Fisher Scientific # 13778500) with either rat
(Origene; SR501698A-C), human (SR321907A-C) or control (SR2004)
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siRNAs according to manufacturer’s instructions. At 48 hours post
transfection, cells were trypsinized and seeded (3x103) in triplicate in 96-well
plates for growth analysis at 24, 48 and 72 hours. Remaining cells were lysed
and assessed by immunoblot as described for total STAT3.
Analysis of publicly available datasets:
IL-28 , IL-28Rα and IL-10Rβ expression levels in control (prostate gland tissue) or
prostate

adenocarcinoma

were

performed

using

the

Oncomine

platform

(www.oncomine.org) [356].
FasL studies:
For PAIII treatment 6X104 cells pre well were seeded in 48 well plates in triplicate and
treated with murine rFasL (R&D Cat # 6128-SA/CF) at varying concentrations. Anti-HA
antibody (2.5ug/ml) was used to trimerize and activate the FasL (R&D Cat #MAB060)
incubated with or without rFasL at 4C for 1 hour while mixing. Subsequent to 48 hours
incubation, cells were lysed, and luminescence was quantified using the Promega
luciferase assay. For cleaved caspase-3 immunofluorescence studies, PAIIIs (F0 or F2)
were seeded into 8-well chamber slides (LAB-TEK #154534) at 2x104 and cultured
overnight before treatment with anti-HA alone, 10ng/ml rFasL+HA or 100nM etoposide
for 5 hours. Cells were then rinsed with PBS and fixed in 4% PFA at room temperature
for 20 minutes. Fixed cells were then blocked for 30 minutes at room temperature in
antibody diluting buffer (2% BSA, 0.1% Triton X-100 in PBS). Primary antibodies
Cleaved Caspase 3, (Cell Signaling Technology #9661S), 1:400 dilution in antibody
diluting buffer; Rabbit IgG Isotype Control, (Thermo Scientific #31235) were incubated
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at room temperature for 30 minutes. Aspirate and Cells were then washed 3x in PBS
and incubated with secondary antibody (Alexa FluorTM Goat Anti- Rabbit 488,
(Invitrogen #A-11034), 1:1,000 dilution in antibody diluting buffer for 30 minutes at room
temp in the dark. After washing 3x in PBS, culture chambers were removed and the
slides mounted with Vectashield Antifade Mounting Medium with DAPI (Vector
Laboratories, # H-1200). Ten representative images from each group were counted and
the number of CC3+ cells were plotted as a percentage to the total number of DAPI
stained nuclei.
QuantSeq analysis:
Total RNA was extracted using biological replicates collected in triplicate from each, F0
and F2 PaIII and F0 and F2 DU145 cell lines using the RNeasy kit (Qiagen Cat# 74104)
followed by DNase treatment using the Max Kit (Qiagen Cat # 15200). RNA
concentrations were measured using the Qubit RNA BR assay and RNA integrity was
assessed using the Agilent 4200 Tapestation. Five hundred nanograms of RNA per
sample was processed by the Moffitt Molecular Genomics Core to generate libraries for
gene expression analysis using the Lexogen QuantSeq 3’ mRNA-Seq Library Prep Kit
FWD for Illumina (Lexogen Cat #015) per manufacturer protocols. At least 20 million
101-base single-end sequencing reads per sample were generated on the Illumina
NextSeq 500 sequencer. The Bluebee Genomics Platform provided with the QuantSeq
kit from Lexogen was used for read for alignment, counting, and differential expression
analysis.
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Statistical analysis:
To determine statistical significance among groups, T-test or analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test was performed. A p-value <0.05
was considered as statistically significant. Data are presented as standard error from
the mean (S.E.M). All statistical analyses were performed using Graph Pad Prism 6.0
(GraphPad Inc. La Jolla, CA). Further analysis of the data was performed by the Moffitt
biostatistics and bioinformatics shared resource cores.
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Chapter 6: Conclusions and Clinical Implications:
The data and results from “Chapter 3: Histone Deacetylase Inhibition Prevents the
Growth of Primary and Metastatic Osteosarcoma” demonstrates for the first time that
osteosarcoma is sensitive both in vitro and in vivo to HDAC inhibition with either the pan
HDAC inhibitor panobinostat or the HDAC 1&2 specific inhibitor romidepsin.
Panobinostat was shown to be effective in reducing tumor burden in primary
osteosarcoma as well as also impairing the growth of established lung metastases and
improving overall survival. The preclinical testing also revealed that pre-treatment with
panobinostat is successful in inhibiting the lung seeding of osteosarcoma cells.
Since

romidepsin

inhibited

osteosarcoma

growth

at

low

nanomolar

concentrations similarly to panobinostat, we postulated that HDAC1&2 are essential to
osteosarcoma growth. To further elucidate whether one or both of these HDACs are
important in supporting the growth of osteosarcoma cells, we used siRNA to knockdown
HDAC1 and we observed an increase of HDAC2 levels conversely when we used
siRNA to knockdown HDAC2 we observed an upregulation of HDAC1 suggesting that
these two HDACs can compensate for each other in osteosarcoma cells. Knockdown of
either HDAC1 or 2 alone had no significant impact on osteosarcoma cell growth but
knockdown of both simultaneously significantly inhibited growth. When we tested both
panobinostat and romidepsin for the treatment of SAOS2LM7, a human lung metastatic
cell line, in vivo, we used immunocompromised mice to allow the human cells to engraft
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in the lungs. In this model, we observed that while both panobinostat and romidepsin
significantly reduced tumor burden in the lungs it was not as efficacious as in the
syngeneic models that we previously used. This observation leads us to believe that
HDAC inhibition may have a role in stimulating an immune response.

Further

investigation of the immune infiltrate into the tumors of mice treated with panobinostat
and romidepsin is needed to confirm this theory. If this is the case, it is possible that
combining immune checkpoint therapies with HDAC inhibition could enhance the
efficacy of both treatments. Further investigation into the changes of protein expression
using RNA sequencing and proteomic analysis after osteosarcoma cells are treated with
HDAC inhibitors will help provide a better understanding of the cellular effects HDAC
inhibition has on osteosarcoma cells. This analysis will reveal more specific targets to
be evaluated as osteosarcoma treatment opportunities.

Overall the results of our

experiments provide the needed preclinical data and rationale to help guide the creation
of clinical trials using HDAC inhibition for lung metastatic osteosarcoma patients that
have failed conventional treatments.

Our data also suggests that it may be useful to

provide HDAC inhibition to primary osteosarcoma patients without detectable lung
metastases as a preventative measure. While our data revealed that HDAC inhibition
was effective for suppressing primary osteosarcoma and the resultant lung metastases,
HDAC inhibition does not appear to be a viable treatment option for mCRPC patients. A
phase 2 trial using romidepsin for mCRPC revealed that there was only minimal
antitumor activity with only 2 of 35 patients showing a partial response [357]. Another
phase 2 trial testing panobinostat for the treatment of CRCP was determined to be not
effective [358]. While HDAC inhibition has yet to be tested specifically for the treatment
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of bone metastatic prostate cancer, we took a different approach in search for a
therapeutic option for the for the metastatic skeletal malignancy. To reveal new
therapeutic options for bone metastatic prostate cancer patients we examined the
cellular and molecular interactions of prostate cancer cells and bone resident
mesenchymal stem cells.
The data and results from “Chapter 5: Mesenchymal Stem Cell-Derived
Interleukin-28 Can Drive the Selection of Apoptosis Resistant Bone Metastatic Prostate
Cancer” reveal that bone-marrow derived MSCs produce IL-28, which triggers rapid
apoptosis of bone metastatic prostate cancer cells via IL-28Rα-STAT1 signaling. That
has known roles in apoptosis, and in anti-viral and immune responses [323]. However,
chronic exposure to MSCs leads to the selection of PCa populations that display a shift
to IL-28Rα-STAT3 signaling leading to resistance to IL-28 induced apoptosis, and to
conventional chemotherapies such as etoposide and docetaxel. Notably, STAT3 is
generally considered to be pro-tumorigenic [324, 328] and is hyperactivated in bone
metastatic prostate cancer [325, 359]. Consistent with these findings, treatment of MSCselected prostate cancer cells with a selective small molecule inhibitor of STAT3, S3I201, impairs their growth and survival ex vivo and in vivo. Thus, the IL-28Rα-STAT3
signaling circuit represents an attractive and therapeutically tractable vulnerability for
bone metastatic prostate cancer.

Our findings also indicate that the application of

STAT3 inhibitors may re-sensitize prostate cancer cells to chemotherapy and that, given
the role of STAT3 activity in the progression of a wide range of cancers [360, 361], the
mechanism described herein may have broad applicability to other skeletal
malignancies and/or metastases.
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If STAT3 inhibition is not effective in treating bone metastatic prostate cancer,
there are other factors revealed in the Quant Seq data that represents possible
therapeutic targets. The human mitochondrion has a circular double stranded genome
that contains 13 protein-coding genes as well as 22 transfer RNAs (tRNAs) and 2
ribosomal RNAs (rRNAs) [362]. In our quant seq data from the human prostate cancer
cell line DU145, 9 of the 13 mitochondrial protein coding genes were downregulated in
the resistant F2 DU145 compared to their F0 parental counterparts (Table 5 and Figure
28). Of the 13 genes highlighted in yellow, 12 are part of the 4 complexes that make up
the electron transport chain (ETC). The downregulation of these genes could possibly
be explained by the fact that resistant cells are undergoing a metabolomic shift toward
glycolysis as explained by the Warburg effect [5]. Suppression of mitochondrial gene
expression was observed in multiple different tumor types when compared to normal
matched tissue [363].

The downregulation of the mitochondrial genes could be

mediated by MSC induced activation of mitochondrial STAT3. Mitochondrial STAT3
enhances that activity of both complex 1 and 2 of the ETC [352, 364], which could be
the reason that mitochondrial genes are downregulated in MSC-educated prostate
cancer cells. The nuclear function of STAT3 as a transcription factor has been well
studied but the roles of STAT3 in the mitochondria are still being discovered. While the
tyrosine phosphorylation of STAT3 at tyrosine 705 is thought to be primarily responsible
for the dimerization and activation as a nuclear transcription factor [365]. STAT3 can
also be phosphorylated at serine 727 by mitogen activated protein kinases (MAPK)
[366]. This serine phosphorylation can cause STAT3 interaction with GRIM-19 a
chaperone that shuttles STAT3 to the mitochondria [367, 368]. There is increasing
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evidence that mitochondrial STAT3 is responsible for cancer progression as well as
resistance to apoptosis.

Mitochondrial STAT3 binding mitochondrial DNA and

regulating gene expression was implicated in tumorigenesis of keratinocytes [369].
Mitochondrial STAT3 has been shown to reduce radical oxygen species (ROS)
increasing the growth in breast cancer cells [370]. Further research is warranted to
study targeting mitochondrial STAT3 to increase therapeutic benefit of other therapies
currently being used for bone metastatic CRPC.
Table 5: Top 20 downregulated genes in DU145 cells after treatment with MSC CM.
Mitochondrial Genes highlighted in yellow

Currently, the only approved therapy that has improved overall survival for bone
metastatic CRPC is radium 223 (also known as Xofigo) [371]. There are currently 38
clinical trials for bone metastatic prostate cancer that are either recruiting or active and
not recruiting. Of the 38 trials 16 of them include radium 223 [146]. A recent trial tested
abiraterone with or without radium 223 in bone metastatic prostate cancer patients.
Abiraterone alone had shown increased overall survival for CRPC patients so
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combination with radium 223 was expected to increase overall survival and decrease in
skeletal related events (SREs) for bone metastatic patients. Unfortunately, for unknown
reasons the trial revealed that addition of radium 223 to abiraterone did not significantly
increase in skeletal event free survival [372]. We hope the results from our studies that
revealed the targeting STAT3 with a small molecule inhibitor effective in treating
apoptosis resistant prostate cancer cells in combination with docetaxel, abiraterone and
or radium 223 might extend overall survival and move us closer to curing bone
metastatic prostate cancer.

Further research is warranted in testing how these

combinations would be best administered.
Adaptive therapy is a concept that incorporates Darwinian evolution and
population ecology principals. Tumors are heterogeneous and contain both sensitive
and resistant cell populations. There are costs for cancer cells that harbor mechanisms
of resistance. In many cases, sensitive cells outgrow resistant populations which make
up a small percentage of the entire tumor. When treatments are administered at the
maximum tolerated dose, they can significantly reduce tumor volume, but this
eradication of the sensitive cells removes the competition for resources in the tumor
microenvironment and allows the resistant cells to reestablish a majority of the tumor
outgrowth [373-375].

This new paradigm in cancer treatment has been effectively

implemented in treating metastatic CRPC. Using a patient specific-dosing schedule of
abiraterone, based on recurring PSA levels, a recent study approximately doubled the
median time to progression from 16.5 months to 27 months while administering half the
standard dosage. [376]. Using the same concept of adaptive therapy has recently been
suggested for use in pediatric sarcomas as well [377].
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Overall, the new data collected in our studies of both primary and metastatic
skeletal malignancies in combination with adaptive therapy will help create new
treatment strategies that will move us closer to a cure for these patients. For example, if
we combined strategies such as STAT3 inhibition in combination with ADT and
chemotherapies, using patient specific adaptive treatment strategies we may be able to
increase overall survival, decrease SREs and move one step closer to curing bone
metastatic prostate cancer.

Similarly, targeting epigenetic vulnerabilities with either

HDAC inhibitors or targeted therapies revealed by HDAC inhibition we can hopefully
increase overall survival for lung metastatic osteosarcoma patients. If administered in
combination with conventional chemotherapies, developing unique treatment strategies
for each patient we hopefully will discover novel treatment strategies that will cure
patients with lung metastatic osteosarcoma.
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